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Abstract 
 
Abdominal aortic aneurysm (AAA) is a complex multi-factorial disease leading to life- threatening 
complications. Chronic inflammation and extracellular matrix degradation are the major pathological 
features of AAA. Vascular inflammation involves complex interaction among inflammatory cells (i.e. 
neutrophils, lymphocytes, monocytes, macrophages), endothelial cells (ECs), vascular smooth 
muscle cells (VSMCs), and extracellular matrix (ECM). Although vascular endothelium plays a key 
role in aneurysm disease, the molecular mechanisms underlying its involvement is only partially 
understood. In this study, we have characterized the role of matrix metalloproteinase-9 (MMP-9) as 
potential trigger of the inflammatory response during the reciprocal interaction between ECs and 
VSMCs.  Briefly, in biopsies of human AAA we found increased level of MMP-9, IL-6 and monocyte 
chemoattractant protein-1 (MCP-1), which correlated with a massive medial neo-angiogenesis. In 
particular, in vitro silencing of MMP-9 in ECs, using specific shRNA delivered by lentiviral vectors, 
inhibited TNF-alpha mediated activation of NF-kB. In addition, ECs void of MMP-9 failed to migrate 
in 3D matrix and affected VSMC behavior in terms of matrix remodeling. Overall our findings 
indicate that silencing of MMP-9 may represent a therapeutic target to restore vascular extracellular 
matrix remodeling. 
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Riassunto 
L’aneurisma addominale aortico (AAA) è una malattia multi-fattoriale complessa che porta a 
complicanze rischiose per la vita. Le principali caratteristiche patologiche dell’AAA sono 
l'infiammazione cronica e la degradazione della matrice extracellulare.  
L’infiammazione coinvolge una complessa interazione tra cellule infiammatorie (in particolare 
neutrofili, linfociti, monociti e macrofagi), cellule endoteliali (ECs), cellule vascolari muscolari lisce 
(VSMC) e la matrice extracellulare (ECM). Anche se l’endotelio vascolare svolge un ruolo chiave 
nello sviluppo dell’aneurisma, i meccanismi molecolari alla base del suo coinvolgimento sono solo 
parzialmente delineati. In questo studio abbiamo caratterizzato il ruolo delle metalloproteinasi-9 
(MMP-9) endoteliale come potenziale agente promuovente della risposta infiammatoria durante 
l'interazione tra EC e VSMC. In particolare, abbiamo rilevato in biopsie di AAA una maggiore 
espressione di MMP-9, IL-6 e monocyte chemoattractant protein-1 (MCP-1), che correla con una 
massiccia neo-angiogenesi presente anche nello strato medio della parete vascolare. È stato valutato 
il silenziamento in vitro di MMP-9 in EC, utilizzando specifici shRNA veicolati da vettori lentivirali, 
ed è stata osservata un’inibizione nell’attivazione di NF-kB a seguito di stimolazione con TNF-alfa. 
Inoltre, le cellule endoteliali private di MMP-9 non sono in grado di migrare in una matrice 3D, e 
influenzano il comportamento VSMC in termini di rimodellamento della matrice. Nel complesso i 
nostri risultati indicano che il silenziamento dell’MMP-9 endoteliale potrebbe rappresentare un 
bersaglio terapeutico per ripristinare il rimodellamento fisiologico vascolare della matrice 
extracellulare. 
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     1.1  Macro- and micro-anatomy of human aorta 
1.1.1 Human aorta  
The aorta is the largest artery of the human vascular system and it is designated to deliver 
blood from heart to the systemic circulation. The human aorta arises from the left ventricle and 
descends to the abdomen; it can be distinguished into distinct segments: ascending aorta (between 
the left ventricle and the aortic arch), aortic arch, descending thoracic aorta (above the diaphragm) 
and abdominal aorta (below the diaphragm). The aorta belongs to the elastic arteries, which are 
large-diameters vessels (larger than 2.5 cm) with close localization to the heart. Healthy aorta of 
an adult normally measured roughly 3 cm diameter at the origin (ascending aorta), 2.5 cm along 
the descending thoracic aorta and 1.8-2 cm along the abdominal aortic segment. Elastic artery 
structure is kept by a network of connective fibres, elastin and collagen, that contributes to the 
arterial distension and recoil during left ventricle contraction (systole) and relaxation (diastole) 
respectively; moreover, the elastic artery recoil allows the blood entering into the small arteries. 
Conversely, the muscular arteries are located at periphery and provide blood to the whole tissue 
(skeletal muscle and inner organs). Muscular arteries are medium-size vessels (about 0.4 cm) and 
they are mainly composed of smooth muscle. This structure is functional to the muscular artery 
ability to vary the laminal diameter depending blood pressure, and regulate blood flow to each 
organ.  
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Figure 1. Human aorta anatomy. Diaphragm divides aorta in two portions: thoracic and abdominal aorta. Virtual dissection 
technology from Anatomage Table (Anatomage, CA, USA) 
 
1.1.2 Structural features of human arterial wall  
The healthy wall of aorta is composed by three layers called tunicae: intima, media and 
adventitia (Gasser et al., 2006) 
 
Figure 2. Microanatomy of a vessel wall.  
Three layers compose arterial wall. The intima and the media are separated by the internal elastic membrane. The external 
elastic membrane separates the media and the adventitia.   
(https://iame.com/online-courses/ultrasound-vascular/vascular-laboratory-markers-of-cardiovascular-risk) 
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Tunica intima is the innermost layer of the artery wall; it consists of a single layer of 
endothelial cells (ECs) placed on a thin basal lamina and a sub-endothelial layer of various 
thickness depending on localization, age and pathological changes. ECs compose the luminal side 
of the vessel wall and they are in contact with the blood flow; ECs are characterized by an 
elongated flat shape, that can undergo changes depending on the direction of the blood flow. ECs 
communicate to each other through a network of three types of junctions: I) tight junctions, or 
zonulae occludens, regulating the substances delivery across the endothelium; II) adherens 
junctions, whose main component is given by cadherins; they are designated to control the 
endothelium permeability to circulating cells; III) gap junctions, structures designated to allow 
ions and metabolites exchange between cells (Bazzoni and Dejana, 2004). ECs possess several 
structural and regulatory roles, participating to the vascular homeostasis and vessel wall integrity. 
They are responsible for the maintaining of a selectively permeable and non-thrombogenic 
barrier, that regulates the smooth muscle cells tone through the secretion of vasoconstrictors and 
vasodilatators, they modulate the immune response through the expression of chemotactic and 
adhesion molecules. ECs are located on the basal lamina, composed of collagen type IV, 
proteoglycans, laminin and fibronectin. Regarding more specifically the abdominal aorta, the 
intima layer is mainly composed by type I collagen (16%), while type III and type IV collagen 
are present in a lower percentage. The sub-endothelial layer mainly contains smooth muscle cells 
and bundles of collagen fibrils. Collagen fibres are not arranged according to the same orientation 
through the whole layer, but many layer of collagen with a distinct pattern of orientation are 
present. (Gasser et al., 2006). The tunica intima terminates with an internal elastic lamina, which 
creates the limit with the medium layer of the artery wall. The internal elastic lamina changes 
according to the arterial type: it is very thin and hard to be distinguished in elastic arteries, whereas 
it is very prominent in muscular arteries. 
The media is the middle and, in terms of mechanical properties, the most important layer 
of the aortic wall. The internal elastic lamina and the external elastic lamina separate the tunica 
media from the intima and adventitia, respectively. The media is composed by smooth muscle 
cells (vSMCs), organized as complex network of elastin and collagen, mainly type I, III, IV and 
V. An extracellular matrix (ECM), containing proteoglycans, surrounds the cellular and elastic 
components. vSMCs are spindle shaped, with an elongated nucleus and assume a specific 
orientation in elastic and muscular arteries. In elastic arteries, vSMCs are arranged into 5-15µm 
thick concentric structures, separated by elastin. At physiological distending pressures, the aortic 
smooth muscle, elastin and collagen are precisely organized into distinct layers, termed lamellar 
unit (Wolinsky and Glagov, 1964). In particular, according to the model of aortic media in 
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mammals proposed by Wolinsky and Glagov, elastin fibres are organized into fenestrated sheets, 
or lamellae, forming concentric layers, with finer elastin fibres that interconnect adjacent 
lamellae; bundles of collagen are interposed between elastin sheets, circumferentially oriented 
(Wolinsky and Glagov, 1964). In a later work, Clarke and Glagov defined the lamellar unit as the 
“musculo-elastic fascicle”, that constitutes both the structural and functional unit of the aortic 
media; the number as well as the orientation and the composition of these units are functional to 
the homogeneous distribution and magnitude of the tensile stress along the vessel wall (Clark and 
Glagov, 2015). Medial vSMCs are essential to the correct functionality of the vasculature; indeed, 
their contraction or relaxation modulate the arterial structural and diameter changes, adapting to 
the blood dynamics and keeping blood pressure. In addition, SMCs are responsible of the 
synthesis of ECM components, vSMCs are susceptible to the phenotype changes, shifting from 
contractile to synthetic, characterized on the basis of different cell shape and structure, marker 
expression, proliferative and migration rates. Contractile vSMCs show an elongated, spindle-
shape morphology, substituted by a less elongated, epitheloid-like shape in synthetic vSMCs. The 
synthetic phenotype is characteristic for the presence of a high number of organelles appointed to 
protein synthesis, as well as for a high proliferative rate. In contractile vSMCs, biosynthetic 
organelles are replaced by contractile filaments; in addition, the contractile SMC phenotype 
presents increased contractile markers, such as alpha-smooth muscle actin, smoothelin, smooth 
muscle heavy chain, that are not represented in synthetic vSMC (Rensen et al., 2007). vSMC 
heterogeneity exists not only between different tissues and vascular districts, but also in the same 
vessel, suggesting a genetic basis. Moreover, vSMC phenotype changes in dearly development: 
during blood vessel formation, vSMCs assume a contractile phenotype, corresponding to a 
reduced ECM production and an increased myofilament formation, allowing the vessel 
contraction and dilation under the effects of blood flow and pressure. A reversal of vSMC 
phenotype, from contractile into synthetic, induces cell proliferation and invasion of the intima 
tunica, characteristic of vascular disorder. Some differences concerning the number of lamellar 
units, the elastic fibres composition and the nutrition mechanism have been observed between the 
thoracic and abdominal region of human aorta, thus, implying a different response to injuries and 
pathological processes. The number of lamellar units increases with arterial diameter and 
mechanical force; in addition, it defines the thickness of the aortic media and influences the 
presence of vasa vasorum, small vessels that arise from the adventitia and supply nutrients to the 
media. When the number of lamellar units is about 28-30 (0.5 mm thickness), as in smaller elastic 
arteries, the media receives nutrients through a simple diffusion mechanism from blood vessel 
lumen, traversing endothelial layer. Arteries with more than 28 units receive nutrient from vasa 
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vasorum. Human thoracic aorta contains 55-60 lamellar units, that increase in number through the 
synthesis of new additional lamellar units; human abdominal aorta, regardless its diameter, has 
20-32 units, that undergo an expansion process without a numerical increase. This difference may 
explain the major elastin content in thoracic aorta than abdominal aorta; in addition, the elastin 
content was shown to decrease with age. A reduced number of lamellar units, a decreased elastin 
content and an inadequate nutrient transport create the structural conditions (loss of stiffness and 
recoil capacity of elastin) that predispose the abdominal aorta to an increased risk of aneurysm 
formation. (Wolinsky, 1970) (Ruddy et al., 2008). The media of muscular arteries has a less-
defined structure, predominantly made of thick smooth muscle layer and an internal elastic 
lamina. Smooth muscle is arranged into concentric layers, whose number can range between 25 
and 35 in larger arteries; these smooth muscle structures are surrounded by connective matrix that 
works as a substrate for the cell components and, meanwhile, contributing to the artery strength 
and force.   
The adventia (tunica adventitia) is the outermost layer of the arterial wall, representing the 
10% of elastic arteries and the 50% of muscular arteries. It is mainly composed of: fibroblast, 
macrophages, collagen and groudmatrix. The adventitia shows a various level of thickness, 
depending on the localization and function of the vessel wall. Type I collagen is the predominant 
component of the connective tissue and polarized light microscopy showed an organization into 
helical structures. The collagen is the main constituent and it contributes to the adventitial 
providing support and strengthen to the arterial wall, preventing the excessive distension of the 
vessels. Nerves and vasa vasorum are also characteristic of adventitial structures. Nerves 
contribute to the regulation of medial smooth muscle activity, through the release of 
neurotransmettitors, like norepinephrine and acetylcholine. Vasa vasorum represent an intra-
vascular network of small vessels, including arterioles, venules and capillars, that can reach the 
media, as a nutritive support to the arteries whose thickness does not allow the nutrient delivery 
through the diffusion from the intima. The structural changes that affect the arterial wall is named 
vascular remodeling, which interests larger elastic arteries more than smaller and muscular ones. 
Ageing represents the main decisive factor for arterial remodeling, mainly characterized by an 
increased thickness of media and, most frequently, intima. In a young healthy subject, the intima 
is very thin; ageing can be responsible of connective tissue alterations, followed by an increase of 
collagen content. Moreover, endothelial cells can be influenced by ageing process both on the 
structural and functional hand. First, can change their morphology, acquiring a bigger size and an 
irregular shape; they can also loose most of their regulatory roles. Endothelial layer can become 
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more permeable, allowing the transit of many substances and vSMC infiltration. These alterations 
characterized the atherosclerotic process.     
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Figure 3. Molecular and cellular events occurring during vascular remodeling.  
In aged arteries, all these events contribute to decrease compliance, resilience, and increase stiffness. ECM, extracellular matrix; 
MMP, matrix-metalloproteinases; NO, nitric oxide; AGE, advanced glycation end-products. (Duca et al., 2016) 
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  1.1.3 Extracellular matrix in vascular tissues  
Extracellular matrix (ECM) is synthesized by vSMCs and adventitial fibroblasts, and 
constitutes the scaffold that supports the structure and the function of the vessel wall, driving its 
biomechanical properties. ECM does not act only as a structural support, but also regulates many 
cell functions, including proliferation, migration, differentiation and morphological changes 
(Daley et al., 2008).  The main ECM components are fibrous proteins that confer tensile strength 
and visco-elasticity to the wall, as well as proteins that contribute to ECM network building. 
Collagen is a tense protein that prevents vessel wall excessive distension. About 26 
members of this family have been identified and their expression and distribution depend on the 
cell type. Vascular cells, type I and type III collagen are the most common types, representing 
30% and 60% of the vascular wall; the remaining 10% is composed type V, XII and XIV collagen 
(Wagenseil and Mecham, 2009). Structurally, the basic unit of collagen is given by a 300 nm 
triple helix. Each chain, called α-chain, contains 338 (type I) and 340 (type II) triplets of the 
aminosequence Gly-X-Y (generally, X is a proline and Y is an hydroxyproline). Post-
trascriptional modifications are required before collagen maturation into a functional protein. 
Crosslinking Lysil-oxidase increases collagen insolubility and tensile strength by crosslinking. 
Lysyl oxidase (LOX) is a copper-dependent amine oxidase that initiates the covalent cross-
linking of collagen and elastin. LOX catalyses an oxidative de-amination of lysine and 
hydoxylysine residues to peptidyl a-aminoadipicd-semialdehydes. These highly reactive 
semialdehydes can spontaneously condense to form intra-and intermolecular covalent cross-
linkages that assure ECM stability. Strong evidence about the involvement of a reduction of LOX 
activity in the pathogenesis of AAA is available. (Rodríguez et al., 2008)  
 
Figure 4. Reaction catalyse by LOX. LOX oxidizes primary amines on collagen and elastin substrates to reactive 
semialdehydes that form by condense covalent cross-linkages. (Rodríguez et al., 2008) 
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Blood vessels are endowed with the property of viscoelasticity, which allows to buffer 
pressure variations during the cardiac cycle, permitting an adequately constant blood flow and 
correct organ perfusion. This mechanical phenomenon is due to the presence of highly resilient 
elastic fibres. They are arranged in concentric fenestrated elastic lamellae. Each elastic lamella 
alternates and it is physically connected with a concentric ring of vSMC forming the lamellar 
unit. Mature elastic fibres and lamellae are comprised of a homogenous core containing elastin 
that is assembled along parallel microfibrils. Microfibrils are composed of numerous 
heterogeneous glycoproteins, such as fibrillin-1 and fibrillin-2, microfibrin-associated 
glycoproteins (MAGP1 and MAGP2) and the latent transforming growth factor β (TGF- β)-
binding proteins (Kielty et al., 2002). Microfibrils interact with other proteins localised to the 
elastin-microfibril interface or to the cell surface-elastic fibre interface called elastin microfibril 
interface-located proteins (EMILINs) and fibulins. However, elastin is the most prominent 
component of the large arteries wall.  
Elastin gene is located on chromosome 7 and its expression is high during pre- and 
neonatal development (Arribas et al., 2006). In humans, its activity is restricted to the early life, 
and the mature form of elastin has a half-life of 40 years. Elastin degradation is related to aging 
and diseases. Elastin gene encodes for a precursor form of the functional protein, named 
tropoelastin. This is a monomeric protein (64-72 kDa), whose structure is characterized by the 
alternans of hydrophobic domains and lysine residues with cross-linking motifs. When 
tropoelastin is released in the extracellular space, lysine residues undergo modifications to form 
covalent binds with elastin molecules. As collagen, crosslinking is mediated by lysil-oxidase and 
takes to sequential reactions leading to the functional and insoluble form of elastin. Unlike elastin 
that has 15-20 cross-links per unit, collagen only contains 1-4 cross-links. The high number is 
critical for elastin recoil property, as well as for insolubility and high half-life (Eyre et al., 1984). 
As reported before, under native conditions elastic fibres have short period of active synthesis, 
restricted to fetal life and neonatal period. During this period, tropoelastin is continuously 
produced and assembled into extracellular elastic fibres. Afterwards, tropoelastin is not actively 
synthesized in blood vessels. The first prerequisite step in elastogenesis involves assembly of 
microfibrils close to the cell surface, probably modulated by the cell surface integrins and heparin 
sulfate proteoglycans. It requires proteolytic modifications of the secreted fibrillins before the 
association with MAGPs and other microfibrillar components. The hydrophobic and non-
glycosylated tropoelastin requires to be chaperoned through the intracellular secretory pathways. 
In the endosomal and Golgi compartments, tropoelastin is escorted by a 67 kDa elastin binding 
protein (EBP) that protects from premature intracellular self-aggregation and degradation by 
16 
 
serine proteinases. This interaction triggers the release of newly secreted tropoelastin from the 
chaperone and their subsequent orderly binding to the microfibrillar scaffold. This systematic 
binding secures a proper mutual orientation of the adjacent tropoelastin molecules and allow for 
the process of ordered self-assembly (coarcevation). Coarcevation allows for the proximity of 
lysine residues (located in “cross-linking domains”) that can be covalently cross-linked together 
after their oxidative deamination by a LOX (Kagan and Li, 2003) to form linkages called 
desmosines and isodesmosine. The fully cross-linked elastin turns into an “insoluble” polymer. 
Vascular elastin is produced by SMCs in the media and fibroblasts in the adventitia, but also 
endothelial cells display some limited elastogenic abilities. Elastin confers elasticity to the vessel 
wall, the most essential property in large diameter arteries which are subjected to high pressures 
generated by heart beating and blood flow, defining their ability to contract and distend according 
to the cardiac cycle. In addition, elastin and elastin-derived peptides (EDP) have been shown to 
regulate cell proliferation and phenotype. 
 
Figure 5. Elastin remodeling.  
During ageing, elastin is subject to remodeling and fragmentation. Different factor such as mechanical fracture, calcification, 
glycation, carbamylation and peroxidation can contribute to elastin fragility and rupture. In addition, these factors enhance elastin 
susceptibility to proteolysis by specific elastases such as serine, cysteine, and MMPs. (Duca et al., 2016) 
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Elastokines are the bioactive EDP generated by the action of elastases and, all elastokines 
act by binding to a singular cell surface receptor named the elastin receptor complex (ERC). ERC 
is derived from the lysosomal β-galactosidase (β-Gal) complex and is expressed at the plasma 
membrane of numerous cell types (Duca et al., 2004). It is a heterotrimer composed of a 
peripheral 67 kDa subunit noted elastin-binding protein (EBP), which binds elastin peptides, a 
55 kDa protective protein or cathepsin A (PPCA), and a 61 kDa membrane-bound neuraminidase, 
Neu-1 (Hinek et al., 2006). From a mechanistic point of view, when an elastin peptide binds to 
EBP, it is recruited to the cell membrane where it interacts with PPCA and Neu-1 to form the 
functional ERC enhancing diverse signaling pathways. Depending on the cell type, various 
signaling modules are triggered, converging to the activation of ERK1/2, which appear as crucial 
actors in elastin peptide signaling. In smooth muscle cells, EBP-induced proliferation involves 
activation of Gi proteins concomitantly with opening of Ca2+ L-type channels. Finally, in 
endothelial cells, a PI3Kγ/Akt/eNOS/NO/PKG1 module is involved in ERK1/2 activation 
(Fahem et al., 2008). 
 
Figure 6. Elastokines signaling.  
Elastin receptor complex (ERC)-induced signaling pathways and associated cellular response. cGMP, cyclic guanosine 
monophosphate; EBP, elastin-binding protein; ERK1/2, extracellular signal-regulated kinase 1/2; MEK1/2, mitogen-activated 
protein kinase/extracellular signal-regulated kinase 1/2; NO, nitric oxyde; PI3Kγ, phosphoinositide-3 kinase γ; PKG, protein 
kinase G.  (Maurice et al., 2013) 
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     1.1.4 Biomechanical properties of human arterial wall 
Vessel wall are continuously exposed to a wide range of hemodynamic forces. Because of 
the pulsatile nature of blood and the complexity of the arterial system, being composed of various 
size vessels, branches and bifurcations, the fluid mechanic laws cannot be simply applied to 
explain these mechanics (Resnick et al., 2003). Blood vessels are constantly subjected to various 
types of hemodynamic forces, including hydrostatic pressure, cyclic stretch, and fluid shear stress. 
Shear stress (τ) is parallel to the vessel wall and represents the frictional force that blood flow 
exerts mainly on the endothelial layer. Instead, cyclic stretch (ρ) is the stress perpendicular to the 
vessel wall and represents the circumferential deformation of the blood vessel wall during 
distension and relaxation of the recurring cardiac cycle. 
 
Figure 7. Mechanical and hemodynamic forces associated with blood flow.  
Shear stress (τ) is parallel to the vessel wall and represents the frictional force that blood flow exerts mainly on the endothelial 
surface of the vessel wall. Instead, cyclic stretch (ρ) is the stress perpendicular to the vessel wall and represents the 
circumferential deformation of the blood vessel wall during distension and relaxation of the recurring cardiac cycle. 
 
Hemodynamic forces associated with blood flow play a central role in the homeostasis of 
the circulatory system. These forces act on the vascular wall, contributing to the regulation of 
myogenic tone, responses to vasoactive molecules, gene regulation, vascular permeability and 
remodeling. Hemodynamic loading breakdown, can be responsible for the development of 
vascular diseases, including hypertension, thrombosis, aneurysms and atherosclerosis. While 
physiological cyclic stretch induces cell cycle arrest in VSMC, chronically increased blood 
pressure and vascular transmural stress activate vascular cell proliferation (leading to luminal 
stenosis), collagen and fibronectin synthesis which results in thickening of the vascular wall as a 
feature of hypertension-induced vascular remodeling eventually altering arteries compliance. 
(Hipper and Isenberg, 2000)(O’Callaghan and Williams, 2000) 
Although vascular endothelial cells and vascular smooth muscle cells are exposed to both 
types of mechanical forces, shear stress resulting from blood flow is sensed mainly by ECs 
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(Davies, 1995), whereas both ECs and SMCs are subjected to cyclic stretch resulting from 
pulsatile pressure. Vascular cells have with numerous receptors that sense external stimuli such 
as strain, pressure and fluid shear stress. These receptors transduce the mechanical signals into a 
biological response through a process named mechanotransduction. The cytoskeleton and other 
structural components have an established role in mechanotransduction, being able to transmit 
and modulate tension within the cell. SMCs and ECs are able to perceive stretch and shear stress 
alterations through a system of receptors, that include integrins, G-protein receptor, ion channels, 
adhesion molecules and activate a signal transduction, also involving extracellular matrix 
(Resnick et al., 2003) (Lehoux et al., 2006).  
As previously described, endothelium works as a selectively permeable barrier that 
regulates the macromolecules entrance from the blood into the vessel wall (i.e. low-density 
lipoprotein, LDL). In this view, endothelium has a protective function, together with an anti-
thrombogenic property; moreover, it guides the inflammatory process and drives the SMC 
contraction through the release of vasocostrictors and vasodilatators. Any impairment in these 
activities is crucial for the development of pathological processes, especially related to 
proatherogenic and pro-thrombotic events. Each shear stress variation is sensed by ECs, that 
undergo several mechanisms of adaptation to acute as well as chronic changes. One of EC 
characteristics consists in the alignment according to the blood flow. Under physiologic condition, 
the mean intensity of shear stress is typically of 10-15 dynes/cm2 in large arteries. (Tsou et al., 
2008) ECs with an elongated shape and aligned with blood flow reflect a laminar and 
unidirectional flow; closely to side branches, bifurcations and curvatures, the flow becomes 
turbulent, creating secondary flows with different directions as well as recirculation sites 
(vortices); in this case, ECs assume a less oriented configuration, a polygonal shape and this 
morphological alteration is mediated by the cytoskeleton and microtubules rearrangement.  
The introduction of DNA microarray technique allowed the identification of a great 
quantity of genes regulated by shear stress, highlighting many molecular mechanisms involved in 
vascular wall pathophysiology. Interestingly, genes encoding for anti-oxidant factors, ECM 
proteins, growth arrest and gap junction proteins were shown to be induced under chronic laminar 
shear stress, revealing an atheroprotective role; conversely, proatherogenic and pro-inflammatory 
genes were stimulated in response to an altered shear stress (Malek et al., 1999) (Li et al., 2005). 
Although shear stress mainly acts on ECs, it can influence SMC phenotype and alignment, in 
mechanism mediated by ECs. According to SMC culture in an in vitro two-dimensional level, a 
laminar shear stress stimulates the acquisition of a contractile phenotype, increases SMC 
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apoptosis mediated by EC release of NO and reduces the cell proliferation (Sterpetti et al., 1993), 
inducing the cell-cycle arrest. Conversely, an oscillatory flow takes to SMC proliferation and 
migration, in a MMP-dependent mechanism, characteristics of the synthetic phenotype. 
Interestingly, SMC proliferation was observed closely to atherosclerotic sites, with high shear 
stress (Yoshida et al., 1990). Differently from shear stress, mechanical stretch directly affects 
SMCs, both at the structural and molecular level. At physiological strain (10%, 1 Hz), SMC 
proliferation resulted inhibited through different mechanism, one of which involves the G1/S 
arrest during cell cycle. All these data are concurrent with the belief that SMC under physiological 
stretch are differentiated and reveal a contractile phenotype. Under hypertensive condition, SMCs 
are exposed to high level of stretch, due to the increased blood pressure and, according to 
Laplace’s equations (T=Pr/h), increased proliferation and enhanced synthesis of collagen and 
elastin (Lehoux et al., 2006). 
From a molecular point of view, SMCs express many different receptors and ion channels, 
which can be activated by mechanical stress leading to the activation of multiple classic signaling 
pathways, such as G protein, kinases, calcium, cAMP, NO, eNOS, MAPK and MKP-1. Moreover, 
mechanical stresses appeared simultaneously to initiate multiple signaling pathways. Mechanical 
stresses stimulate conformational activation of cell integrins and increase cell binding to 
extracellular matrix. The dynamic formation of new ligand-integrin connections is required for 
stretch induced mechanotransduction. During the stimulation of vascular cells by mechanical 
factors such stretch, several signaling events are associated with the formation of focal adhesion, 
which comprise integrin cluster and cytoskeletal protein. The proteins present at focal adhesion 
become phosphorylated on tyrosine when the cells are stimulated, a FAK activation is an indicator 
in focal adhesion formation (Boccafoschi et al., 2011)(Lehoux et al., 2006).  
Once cells adhere to ECM proteins, integrins became activated and form cluster at the cell 
surface thus initiating the formation of adhesion complexes which will enhance FAK’s catalytic 
activity and increase FAK tyrosine phosphorylation. FAK phosphorylation at tyrosine 397 (Y397) 
leads to the recruitment of Src and Src-family kinases as well as to an increased phosphorylation 
of other proteins present in the adhesion complex such as paxilin and p130Cos. (Arias-Salgado et 
al., 2003) (Lehoux et al., 2005) Subsequent phosphorylation of specific tyrosine residues leads to 
the recruitment of additional SH2-domain-containing signaling proteins such as PI3K and 
Grb2.43 Among integrin receptors, integrin α5β3 has been identified as having particularly 
interesting expression pattern among the vascular cells during angiogenesis and vascular 
remodeling. In particular, integrin α5β3 binds numerous ECM ligands with exposed RGD peptide 
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as fibronectin, vitronectin, fibrinogen and it is involved in the response to mechanical strain. In 
the ‘90s, Wilson and colleagues established a link between the mechanical stimuli and the action 
of growth factors. Their studies demonstrated that cyclic stretch increased VSMC proliferation 
when plated on collagen, fibronectin or vitronectin, but not on laminin or elastin; further, these 
effects required the production of PDGF suggesting a tight interaction between integrins and 
growth factors downstream signaling pathways related to mechanical stimuli. Generally, growth 
factors receptors belong to two classes of membrane proteins: tyrosine kinase receptors and G-
coupled receptors and G proteins. Another membrane structurse involved in mechanosensing are 
ion channels. VSMCs stimulated by mechanical stress result in a transient increase in intracellular 
calcium and divalent cations and depolarization which maintain smooth muscle tension. Opening 
these channels causes Ca2+ and Na+ influx and membrane depolarization, which contributes to the 
myogenic response to mechanical stretch. (Marrero et al., 1996)  
The altered stretch-activated channels in arterial SMCs may contribute to the enhanced 
myogenetic responses as well as the generation of hypertrophy and remodeling of arterial tissue 
in hypertension. All the cited membrane mechanosensors have a common intracellular pathway 
converging to MAP kinase signaling. MAP kinase comprises a ubiquitous family of 
threonine/tyrosine kinases, and includes extracellular signal-regulated kinases (ERK), stress 
activated protein kinases (SAPK) or c-Jun NH2-terminal kinases (JNK) and p38/ERK kinases. 
(Karin, 1998) This cascade is an important pathway whereby signal originating from mechanical 
forces can lead to gene expression and protein synthesis in vSMC. 
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1.2  Abdominal Aortic Aneurysm  
 
1.2.1 Definition, epidemiology and risk factors  
The term “aneurysm” is used to define a permanent focal dilatation of the vessel wall. Mc 
Gregor et al. defined abdominal aortic aneurysm (AAA) as an aortic segment with a diameter 
larger than 3cm  (McGregor et al., 1975); following this definition, aneurysms of the infrarenal, 
intrarenal and suprarenal aorta are included (Sakalihasan et al., 2005). Aneurysms can be 
distinguished into fusiform and saccular, according as the whole aortic circumference, or only a 
small segment of the aortic circumference, is interested.  
 
 
Figure 8. Type of aneurysms (stanfordhealthcare.org) 
AAAs comprise the 15th leading cause of death among men over 65 and result in more 
than 15,000 surgical procedures annually in the United States. Although prevalence of aneurysms 
is increasing the mechanisms that regulate aortic aneurysm development remain almost undefined 
(Lederle et al., 2000) (Salmon et al., 2013). Approximately 80% of all aortic aneurysms occurs 
below the renal arteries, and the majority has an atherosclerotic cause. Other less common causes 
include inflammatory aneurysm, tuberculous aneurysm and syphilitic or infectious aneurysm. 
It usually remains asymptomatic until the rupture occurs. Because of the ageing of the 
population, the increasing of smokers and the improved screening and diagnostic tools AAA 
incidence is recently increased. Major risk factors for the occurrence of AAA are male gender, 
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age, smoking, race, pre-existent cardiovascular affections, such as hypertension and 
atherosclerosis. The risk of AAAs increases dramatically after 60 years of age (Singh, 2001). 
Clinically relevant aneurysms (more than 4 cm in diameter) are present in approximately 1% of 
men between 55 and 64 years of age, and the prevalence increases by 2% to 4% per decade 
thereafter (Singh, 2001). AAAs are four to six times more common in men than in women (Scott 
et al., 1995) (Lederle et al., 2001). Moreover, AAAs develop in women approximately 10 years 
later than in men (McFarlane, 1991). The related mechanisms of sex differences are not fully 
understood, although women seem to be protected by female sex hormones (Makrygiannis et al., 
2014).  
AAAs were found to occur more frequently in Caucasian population than in Afro-
American ethnicity. Due to its promoting effects on inflammation, proteolysis, and smooth muscle 
cell (SMC) apoptosis, smoking is another strong risk factor for the development of AAAs. (Li 
and Dai, 2012). In addition to these environmental components, genetic aspects play an important 
role. A positive familiar history for AAA, especially in male first-degree relatives, is associated 
with an increased risk. Rupture of an AAA and its associated catastrophic physiological insult 
carry the overall mortality more than 80%, and 2% of all deaths are AAA-relate (Nordon et al., 
2011).  
Most aneurysms are small in size and they do not need the surgical repair, but the increase 
in the aortic diameter can lead to rupture, which can be fatal. Medical therapy may be helpful in 
patients with small- to medium-sized aneurysms not elective for surgery (thoracic and abdominal 
aortic aneurysms). Appropriate and immediate therapy is essential with the aim of stabilizing the 
patient and improving the clinical outcome. Therapy’s targets are blood pressure control, decrease 
of shear stress, optimization of anticoagulation, volume management, and pain control. Different 
pharmacological treatments are available: beta-blockers, tetracycline, statins and angiotensin-
converting enzyme Inhibitors/Angiotensin Receptor Blockers. β-blockers may be beneficial for 
reducing the rate of aortic dilatation. This is thought to be due to the effect of β-blockers in 
reducing left ventricular dP/dt and reducing shear stress. In addition, β-blockers reduce dP/dt in 
the aorta and might be beneficial via this mechanism and the resultant effect on shear stress in the 
aorta (Danyi et al., 2011). Although data regarding therapeutic benefit of beta-blockers in 
management of AAA are limited, beta-blockers have been shown to significantly reduce the 
expansion rate of AAA. The 2005 ACC/AHA guidelines recommended beta-blocker therapy in 
patients with an AAA not elective for surgery. Doxycycline is a nonspecific MMPs inhibitor 
(Petrinec et al., 1996). This antibiotic has been used in conditions with MMPs overexpression 
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(e.g., periodontal disease, rheumatoid arthritis) (Hanemaaijer et al., 1997). In animal models, 
doxycycline slowed elastin degradation and aneurysm development (Xiong et al., 2008). In 
human, doxycycline decreased MMP-9 levels (Baxter et al., 2002) and slowed the rate of 
progression of AAA. Statin treatment is one of the elective therapies in cardiovascular diseases. 
Statins reduce the progression of atherosclerosis and improve clinical outcomes. In addition to 
their lipoprotein-reducing properties, statins have pleiotropic effects. For instance, they reduce 
oxidative stress by blocking the effects of reactive oxygen species on aneurysms. This effect is 
independent of their lipid-lowering properties. Statins achieve these results through suppressing 
the NADH/NADPH oxidase system (Ejiri et al., 2003). Angiotensin II has been shown to have 
several biological effects on the cardiovascular system. It promotes vascular hypertrophy, cell 
proliferation, production of extracellular matrix, and activation of macrophages, and it activates 
NADH/NADPH oxidase of vascular smooth muscle cells. Angiotensin-converting enzyme 
inhibitors (ACEIs) have been shown to both stimulate and inhibit MMPs and the degradation of 
extracellular matrix in aortic aneurysms (Rizzoni et al., 2003).  
 
Figure 9. Molecular mechanisms of aneurysm formation and the effects of different medications. Angiotensin promotes 
aneurysm formation through angiotensin 1 (AT1) receptors, increasing ROS via NADH/NADPH system. This promotes 
inflammatory reaction and subsequent medial degeneration, leading to AAA. Fibrillin gene mutations cause enhanced 
transforming growth factor (TGF)-β signaling, causing cell proliferation and MMP synthesis. Angiotensin-converting enzyme 
inhibitors (ACEIs) block angiotensin II. Statins block the NADH/NADPH system; tetracyclines and macrolides reduce MMP 
activity. β-Blockers reduce shear stress on the vessel. (Danyi et al., 2011) 
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1.2.2  Symptoms, diagnosis and treatment 
Differently from inflammatory AAAs, non-inflammatory aneurysms are generally 
asymptomatic: only in 8-18% of AAA cases, patients reported symptoms (i.e. pain that radiates 
to back or legs or low blood pressure). For this reason, AAA are accidentally diagnosed, after 
clinical investigation in presence of other cardiovascular disease or during screening test. In order 
to confirm a diagnosis of AAA, a complete medical history and physical examination is performed 
in combination with instrumental diagnostic procedures such as: X-ray, computed tomography 
scan (CT-scan) and magnetic resonance imaging scan (MRI).  
Conversely, rupture of aneurysm is accompanied by abdominal pain, hemorrhagic and a 
pulsatile abdominal mass. Aneurysm evolution and possible complications are generally 
evaluated by diameter measures, which represent the major index of aortic rupture risk. The use 
of non-invasive techniques detecting circulating levels of degradation peptides or proteins that 
actively participate to AAA molecular pathogenesis would be more useful and accurate to decide 
drug therapy or surgical intervention. About 30% of asymptomatic aneurysms are recognized by 
physical palpation as a pulsatile abdominal mass, but this type of inspection bears on inter-
operator variability. Preferential diagnostic is represented by ultrasonography (UT), also applied 
to follow-up, surveillance of asymptomatic aneurysms and screening. UT has a high sensitivity 
and sensibility, without high costs. When surgical procedures are needed, CT is performed. It can 
also be helpful to define the best surgical approach. CT gives more detailed information about the 
aortic diameter, the shape of the aneurysm, the thickness of intraluminal thrombus, together with 
the presence of entrapped blood. In presence of an inflammatory AAA (IAAA), CT also indicates 
the extent of the inflammation. MRI is an alternative and more accurate diagnostic procedure, but 
it requires quite expensive cost.  
The treatment choice depends on the aortic size and diameter (Sakalihasan et al., 2005): 
· aortic diameter less than 5 cm: follow-up and surveillance through UT; 
· aortic diameter between 5 and 5.5 cm: follow-up or surgery (the latter in case of female patient, 
familial history, high serum markers such as, plasma fibrinogen, D-dimer and IL-6) 
· aortic diameter larger than 5.5 cm: surgery. 
The goal for abdominal aortic aneurysm is to prevent rupture by controlling wall dilatation 
and weakening. Two different treatments for AAA are reported: open repair or endovascular 
repair.  
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Open surgical repair (OSR) was first reported in 1962 and still remains the treatment with 
the best long-term results. It is a major surgical procedure done under general anaesthesia, usually 
consisting of a midline laparotomy and cross-clamping of the aorta and iliac vessels. OSR is 
followed by the removal of the dysfunctional aortic segment and the insertion of a graft as 
substitute (DuBost et al., 1952). The mortality rate for OSR is between 3% and 7% and increases 
significantly in patients with comorbidities, particularly with coronary and carotid artery disease.  
 
Figure 10. Open surgical repair (A) Abdomen of AAA patient (B) Abdominal CT showing aorta dilatation C) Aneurysm 
sac during surgical open repair D) Abdominal aortic graft in Dacron. Courtesy of Dr. Casella 
 
The development of Endovascular Aneurysm Repair (EVAR) opens the way for a safer 
management of AAA. The long-term results of EVAR are comparable to those of OSR. EVAR 
was first described by Parodi in 1991. (Parodi et al., 1991) Juan Parodi implanted the first 
endograft in a human body and EVAR has become a milestone in the treatment of AAA, 
especially in presence of significant comorbidities. EVAR consists of the placement of a tubular 
graft within the aneurysm sac, using a metallic stent to fix it to the normal aortic and iliac wall. 
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The graft acts like an artificial blood vessel, excluding the damaged aortic segment from the 
normal blood flow, and thus, preventing the aneurysm progression and rupture. This reparative 
alternative does not require the surgical incision of the abdomen, thus avoiding complications 
consequent to the open surgery; in addition, it allows a shorter recovery time, reduced hospital 
stay and implies a lesser blood loss improving the patient quality of life. (Paravastu et al., 2014)  
Several devices are available to treat AAA, differing with respect to design, modularity, 
metallic composition and structure of the stent, thickness, porosity and possible presence of an 
active method of fixing the device to the aortic wall. Appropriately-sized aortic endograft should 
be selected in relation to patient anatomy. The ideal characteristics are: 
ü Stent-graft size ranging 
ü Long durability  
ü Good biocompatibility  
ü Device delivery flexibility  
ü Radial force stability  
ü Low overall costs 
 
Figure 11. Open surgical repair (A) and Endovascular repair (B). (Schermerhorn et al., 2008) 
 
One of the most frequent cause of EVAR failure is the “endoleak”, which happens when 
the blood flows into the aneurysm sac, external to the graft, and this condition can lead to 
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aneurysm expansion and rupture. Endoleak can be detected by angiography, CT scan or duplex 
ultrasound imaging and can be classified according to the timing of development. Primary 
endoleak (early endoleak) includes all cases that occur during the 30 days’ perioperative period; 
secondary endoleak (late endoleak) represents a late complication of the correct seal (White et al., 
1997). Endoleaks are further distinguished into five different types: type I, occurs when there is 
persistent blood flow around the proximal end of the graft or around the distal aspect of the graft; 
type II is caused from back-bleeding from side branches (inferior mesenteric artery and lumbar 
arteries) that retrograde fill the aneurysm sac; type III, derived from a mechanical failure or a 
structural defect of the graft; type IV, consequent to a graft wall porosity; type V, often referred to 
as “endotension,” it happens when the aneurysm sac becomes pressurized without an identifiable 
source. (White et al., 1998)(Baum et al., 2003) 
 
 
 
Figure 12. Classification of endoleaks.  
(https://academic.oup.com/eurheartj/article/35/41/2873/407693/2014-ESC-Guidelines-on-the-diagnosis-and-treatment) 
 
Although many researchers suggest that aneurysm formation is due to a combination of 
genetic, environmental and immune factors (Sakalihasan et al., 2005), the most common form of 
this dilatative affection rises consequently to atherosclerotic plaque disease, except in specific 
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cases of aneurysms associated with inflammatory diseases, connective tissue affections or 
traumatic event. The theory on the atherosclerotic origin of AAA has been based on the presence 
of atherosclerosis pathogenesis features in patients affected by aortic aneurysm. Current 
investigations and data about the specific nature of this relationship are still controversial; in 
addition, the aetiology and the key mechanisms involved in aneurysm initiation and expansion 
have not been completely elucidated. However, common features of aortic aneurysms are 
inflammation, matrix degradation and smooth muscle cells depletion. According to the most 
established theory, the “atherosclerotic aneurysm” develops as a complication to the pathological 
processes deriving from the atherosclerotic plaque development: matrix remodeling, thrombus 
formation and release of pro-inflammatory cytokines. An alternative theory considers aneurysm 
and atherosclerosis as independent events, that result from the same environmental and genetic 
conditions, but different dynamics are involved. In any case, according to current data describing 
the type of association between the two arterial affections, the majority of AAA are associated 
with atherosclerosis and elucidating this process would be crucial to develop more specific and 
targeted therapies. In the following table 1, major features of both atherosclerosis and AAA are 
listed.   
 
Table 1.  Differences between atherosclerosis and AAA. (Peshkova et al., 2015) 
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     1.2.3 Histological features of AAA 
The destruction of the lamellar architecture of the aortic media is the predominant 
histopathological feature of aneurysm disease. As previously described, ECM represents the 
dynamic structure that supports the aortic wall, driving its main functions. ECM remodeling is 
strictly regulated under physiological conditions and abnormal expression and activity of the main 
ECM remodeling mediators are characteristic of many vascular disorders. Elastin fragmentation 
represents an early event in AAA formation, consequently causing wall weakening; degradation 
of fibrillar collagen type I and III occurs in a later phase of the AAA expansion, leading to the 
loss of aortic tensile strength and causing a decisive step in the aortic rupture. Many experimental 
data, obtained from human aneurysm tissues, as well as from in vitro and in vivo animal models, 
highlighted the MMPs involvement in ECM abnormal degradation, evidenced by an increased 
expression of these proteolytic enzymes during aneurysm initiation and/or progression, 
correlating with aneurysm size. MMPs are secreted by vascular and inflammatory cells; MMP 
over-expression in terms of mRNA, protein, as well as enzymatic activity, is not only associated 
with an increased production and secretion, but it is also the result of the unbalanced 
MMPs/TIMPs ratio. MMP-2 and MMP-9 are the most commonly enzymes associated with 
aneurysm disease. They both degrade elastin and collagen. MMP-2 is constitutively expressed in 
small aneurysm, suggesting a role in aneurysm initiation and formation, whereas MMP-9 is more 
prevalent in large diameter aorta, indicating a main participation in aneurysm progression and 
expansion. In addition, MMP-8 is a type I collagenases and, together with MMP-9, was shown to 
be increased in ruptured aneurysms. In addition to MMPs, other proteases localize at aneurysm 
wall: u-PA (urokinasePlasminogen activator) and t-PA (tissue-Plasminogen activator) convert 
plasminogen into plasmin, which in turns activates MMPs; cathepsin S and K, with elastolytic 
action, and cathepsin L, which degrade type IV and V collagen, laminin, elastin and 
proteoglycans. Medial SMCs constitute the main vascular cell population that participate to aortic 
structure, through the synthesis of ECM components as well as the secretion of ECM remodeling 
mediators, like MMPs and their tissue inhibitors TIMPs. The importance of SMC behaviour in 
the aneurysm development was explored by Lopez-Candales et al, underlining an increased SMC 
apoptosis, marked by an increased expression of p53, which is indicative of cell cycle arrest, in 
aneurysmal tissues versus non-aneurysmal and atherosclerotic aortic tissues (Lopez-Candales et 
al., 1997)(Holmes et al., 1996). The elastin degradation is tightly related to the abnormal 
hemodynamic shear stress that influences aneurysm growth. The SMCs respond to elastin 
degradation through an increased tropoelastin synthesis; this is confirmed by increased mRNA 
levels of tropoelastin in aneurysm tissue. This adaptation is not followed by the correct elastin 
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organization into the mature effective structures, resulting in the aortic wall inability to respond 
to the increased shear stress.  
Moreover, another feature of AAA is the intraluminal thrombus (ILT). In 70–80% of AAA 
patients, the vessel wall is covered by an intraluminal thrombus which generally does not preclude 
blood flow and shows little compression throughout the cardiac cycle (O’Leary et al., 2014)(Vorp 
et al., 1996). While mural thrombosis is frequently observed in aneurysmal disease, the complete 
vessel occlusion is a comparably rare event associated with a high rate of mortality (Cervantes et 
al., 1985). In recent studies, more attention has been dedicated to the mechanical properties of the 
ILT. Indeed, the mechanical role of ILT on the wall stress distribution and the underlying local 
wall strength is yet unclear.   
In addition to the loss of structural integrity, aortic aneurysm is characterized by an 
intensive transmural inflammation. The presence of the inflammatory infiltrate may be due to 
elastin fragmentation. In fact, this process releases soluble peptides exerting a chemotactic effect 
that recruits inflammatory cells, which further secrete proteolytic enzymes, thus amplifying the 
ECM degradation. Studies on the inflammatory infiltrate invading the AAA wall revealed the 
presence of aggregating clusters of CD3+ T and CD19+ B lymphocytes, together with 
macrophages, and localized at the adventitial vasa vasorum (Koch et al., 1990). In addition, an 
imbalance of the ratio between CD3+ T helper and CD8+ T suppressor cells has been observed, 
with the predominance of T-helper cells (Koch et al., 1990) (Tang et al., 2005). Inflammatory 
cells activate a cascade of reactions increasing inflammation environment and exacerbating the 
proteolysis process. CD3+ T lymphocytes produce IL-4, -5, -8, -10 that attract other inflammatory 
cells, stimulate the cytokine release by T cells and the neoangiogenesis; in addition, CD3+ 
stimulate the IFN-γ release, which, in turn, induces MMP expression. The presence of antigen 
presenting cells in aneurysm wall suggests an antigen driven T cell response as leading cause to 
aneurysm development. Matrix proteins, such as elastin, collagen, aortic aneurysm antigenic 
protein-40 (AAAP-40) (Xia et al., 1996) and exogenous agent (i.e. herpes simplex virus, 
cytomegalovirus) have been proposed as potential antigen capable to induce T cells activation. 
Interestingly, the molecular mimicry is mechanism of T cells activation, and it is supposed to be 
involved in aneurysm pathogenesis. The molecular mimicry is based on sharing of common 
sequences and epitops between a foreign antigen (a microorganism) and self (host) antigen: the 
immune reaction against a virus or bacteria, through a mechanism of cross reaction (Ozsvath et 
al., 1996)(Oleszak et al., 2004). As-consequence, the immune response inside the aortic wall is 
exacerbated, thus complicating the proteolytic process. According to these findings, an 
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autoimmune origin of AAA has been proposed (Hirose and Tilson, 2001). Macrophages actively 
participate to parietal remodeling and inflammation: immunohistochemical and in-situ 
hybridization data revealed an intensive MMP-9 expression by aneurysm-infiltrating 
macrophages (Thomson et al., 1995); later works demonstrated the macrophage-mediated release 
of cytokines, such as Il-1β, TNF-α, IL-8, thus stimulating B-cell and cytotoxic T-cell 
differentiation, cytokine and protease synthesis. Neo-angiogenesis consists in the formation of 
new blood vessels from pre-existing ones and for this purpose it requires the ECM degradation 
by proteolytic enzymes to promote the ECs migration from mature vessels; these steps are driven 
by specific growth factors, such as VEGF, PDGF, EGF, TNF-α. The occurrence of 
neovascularisation in AAA wall has been demonstrated by Thomson et al (1995), evidenced by 
an increased number of neo-vessels in aneurysmal tissues in comparison to normal aortic 
specimens; moreover, the degree of neovascularisation was shown to be correlated with the 
inflammatory infiltrate amount (Holmes et al., 1995). These findings, together with 
immunolocalization studies showing MMPs expression in correspondence of neo-vessels (Herron 
et al., 1991), support a crucial role for the medial neo-vessels formation to the aneurysm 
pathogenesis. Moreover, increased neovascularisation and expression of angiogenic cytokines 
were detected at the site of rupture, indicating an involvement of the angiogenic response into 
aneurysm rupture. 
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Figure 13. Schematic diagram of the mechanisms involved in abdominal aortic aneurysm, which primarily affect two 
main processes: inflammation and extracellular matrix turnover (F. a M. V. I. Hellenthal et al., 2009). 
 
1.3  The MMP family 
The mammalian MMPs are a group of 23 structurally related enzymes that have a catalytic 
Zn2+ ion site (Nagase et al., 2006; Visse and Nagase, 2003). MMPs belong to the family of 
proteolytic enzymes that degrade several components of ECM. MMPs generally consist of a 
prodomain, a catalytic domain, a hinge region, and a hemopexin domain. The cysteine switch 
motif PRCGXPD in the propeptide that maintains MMPs in their zymogen form (proMMP), and 
the zinc-binding motif HEXGHXXGXXH in the catalytic domain is used to distinguish the 
proteinases family. They are either secreted from the cell or anchored to the plasma membrane. 
On the basis of substrate specificity, sequence similarity, and domain organization, vertebrate 
MMPs can be divided into six groups (Figure 14).  The key feature of collagenases (MMP-1, 
MMP-8, MMP-13 and MMP-18) is the ability to cleave interstitial collagens I, II, and III at a 
specific site. MMP-2 and MMP-9 also belong to collagenases group. They digest denaturated 
collagens, gelatin. These enzymes have three repeats of type II fibronectin domain inserted in the 
catalytic domain, which bind gelatin, collagen and laminin.  
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Stromelysin’s group are: stromelysin 1 (MMP-3) and stromelysin 2 (MMP-10) with similar 
substrate specificities, while MMP-3 has a proteolytic efficiency higher than MMP-10. MMP-11 
is called stromelysin 3, but it is usually grouped with “other MMPs” because the sequence and 
substrate specificity diverge from those of MMP-3.  
Matrilysins are characterized by the lack of hemopexin domain. Matrilysin 1 (MMP-7) and 
matrilysin 2 (MMP-26) belong to this group. MMP-7 processes cell surface molecules such as pro-
α- defensin, Fas-ligand, pro-tumor necrosis factor (TNF-α), and E-cadherin, while MMP-26 
digests several ECM components. There are six membrane-type MMPs (MT-MMPs): four are 
type I transmembrane proteins (MMP-14, MMP-15, MMP-16 and MMP-24) and two are 
glycosylphosphatidylinositol (GPI) anchored proteins (MMP-17 and MMP-25). Seven MMPs are 
not classified in the above categories. MMP-12 (mainly expressed by macrophages) digests elastin 
and other ECM molecules. MMP-19, MMP-20, MMP-22, MMP-23 and MMP-28 are part of this 
group. 
 
Figure 14. Classification of MMP family. The main features of matrix metalloproteinases (MMPs) are illustrated, showing the 
minimal domain structures. One clear division is between MMPs that are secreted and those that are anchored to the cell surface 
by an intrinsic motif namely, a transmembrane (TM) domain (MMP-14, -15, -16 and -24), a glycosylphosphatidylinositol (GPI) 
anchor (MMP-17 and MMP-25) or an amino (N)-terminal signal anchor (SA) (MMP-23). Nine MMPs, including all of the 
membrane-anchored enzymes, have a furin-recognition domain. C5, type-V-collagen-like domain; Col; collagenase-like protein; 
Cs, cytosolic; Cys, cysteine array; Fn, fibronectin repeat; Fr, furin-cleavage site; Pro, pro-domain; SH, thiol group; SP, signal 
peptide; Zn, zinc.  (Parks et al., 2004) 
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All MMPs are synthetized as pre-pro-enzymes and secreted as inactive pro-MMPs. Many 
of the MMPs have the ability to cleave and activate the pro-forms of other MMPs, thereby acting 
in protease cascades that amplify their effectiveness (Nagase et al., 2006) (Visse and Nagase, 
2003). One of the features of MMP is that many of those genes are “inducible” by different 
effectors such as growth factors, cytokines, chemical agents, physical stress, and oncogenic 
cellular transformation. Moreover, MMPs are regulated at different levels: gene expression, 
localization (that is, the pericellular accumulation of enzyme), pro-enzyme (or zymogen) 
activation and enzyme inactivation (Ra and Parks, 2007). Also, endogenous tissue inhibitors of 
MMPs (TIMPs) provide a balancing mechanism to prevent excessive ECM degradation. An 
imbalance between MMPs and TIMPs could lead to MMPs activity increasing and, thus, to 
pathological changes in the vessel wall structure associated with vascular disease (Raffetto and 
Khalil, 2008)  
 
1.3.1 Focus on human MMP-9  
Human MMP-9 consists of an NH2- terminal pro-domain, a catalytic domain, a linker 
domain, and a COOH-terminal hemopexin-like domain that combines to form a 92 kDa pro and 
88 kDa active enzyme. (Papazafiropoulou and Tentolouris, 2009)  The catalytic domain of MMP-
9 contains two zinc ions, five calcium ions, and three repeats homologous to the type II module 
of fibronectin. The catalytic zinc ion is essential for the proteolytic activity. MMP-9 has a unique 
domain termed “fibronectin-like domain”, which consists of three repeats of fibronectin type II 
of about 58 amino acids. This domain is heavily O-glycosylated and contains elongated linker 
between catalytic and hemopexin-like domain (Opdenakker et al., 2001). The fibronectin-like 
domain is essential for binding to denatured collagen or gelatin (O’Farrell and Pourmotabbed, 
1998). Hemopexin-like domain shares a sequence similarity to plasma hemopexin and it is present 
in MMP-9. In pro-MMP-9, the hemopexin-like domain forms a tight complex with TIMP-1 and 
TIMP-3 though their COOH-terminal domains (Nagase et al., 2006), Pro-MMP-9 is complexed 
with TIMP-1 in the Golgi apparatus of the cell before secretion (Roderfeld et al., 2007). TIMP-1 
is bound to the pro-MMP-9 via COOH-terminal domain, leaving the NH2 terminus capable of 
inhibiting other MMPs.  
The expression of MMP-9 is regulated on multiple levels: transcription, post-translation 
(also involving non-proteolytic activation); local translation (Dziembowska et al., 2012); 
sequestration on the cell membrane (e.g. binding to cell adhesion molecules, such as hyaluronian 
receptor CD44 (Bourguignon et al., 1998), integrins (Wang et al., 2003), lipoprotein receptor-
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related protein-1 (LRP-1), and megalin/LRP-2 (Van den Steen et al., 2006)); internalization 
(Hahn-Dantona et al., 2001); and delayed activation that involves cleavage of the propeptide and 
co-secretion with TIMP-1, its endogenous inhibitor (Sbai et al., 2010).  
At the transcriptional level, MMP-9 is positively regulated by multiple factors, including 
E-26 (Ets) transcription factors, NF-kB, polyomavirys enhancer A-binding proteins-3 (PEA3), 
activator protein-1 (AP-1), specificity protein 1 (Sp-1), and serum amyloid A-activating factor 
(SAF)-1 (16). Ets are a family of transcription factors associated with a variety of biological 
functions including cellular differentiation, cell migration, proliferation, apoptosis and 
angiogenesis. NF-kB is capable of binding to kB DNA on the promoters or enhancers of genes to 
regulate expression. Bond et al.  reported an increase in MMP-9 levels in vascular smooth muscle 
cells via NF-kB mechanisms (Bond et al., 2001a). Inhibition of transcription factor NF-κB reduces 
MMP-9 production in vascular smooth muscle cells and macrophages (Bond et al., 2001) (Grimm 
et al., 2006). Reactive oxygen species can activate MMP-9, both directly and indirectly, by 
activating transcription factors such as NF-κB (Okamoto et al., 2001). Ang II has direct and 
indirect effects on MMP-9 expression. In ventricular myocytes, Ang II directly stimulates NF-κB 
to induce MMP-9 expression (Rouet-Benzineb et al., 2000). Ang II activates epidermal growth 
factor receptor and the mitogen-activated protein kinase pathway to induce MMP-9 expression 
(Shah and Catt, 2003). Aldosterone, which is produced locally in the myocardium, triggers MMP-
9 production through NF-κB signaling (Li et al., 2000). PEA3 and AP-1 binding sites are present 
in the MMP-9 promoter (Wu et al., 2009). AP-1 has two binding sites on MMP-9, and the 
activation of MMP-9 is preceded by a rapid transient increase in AP-1 protein levels (Woessner, 
1991). Thrombospondins stimulate production of MMP-9 by activating AP-1 (Greenwood et al., 
1998). Donnini and colleagues showed that fragments of thrombospondin promote MMP-9 
production in bovine capillary endothelial cells (Donnini et al., 2004). In order to increase 
transcription, Sp-1 binds to the MMP-9 promoter to induce transcription. Sp-1 undergoes several 
post-transcriptional modifications such as phosphorylation and glycosylation (Murthy et al., 2012) 
(Taheri and Bazan, 2007). Conversely, inhibition of Sp-1 leads to decreased MMP-9 expression 
(Murthy et al., 2012). In addition, the transcription factor described above cross-interact to regulate 
MMP-9 expression. In fact in vascular smooth muscle cells, upregulation of MMP-9 is mainly 
attributed to expression and activation of NF-κB and AP-1 transcription factors (Valen et al., 
2001).  AP-1 alone, however, is not sufficient for maximal MMP-9 transcription, and the 
cooperation of either NF-κB or Sp-1 binding proteins upstream of the AP-1 site is required for full 
MMP-9 transcription induction (Benbow and Brinckerhoff, 1997). SAF-1 is an inflammatory 
responsive transcription factor that induces MMP-9 transcription via cooperation with AP-1 (Ray 
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et al., 2005). In the MMP-9 promoter region, SAF-1 is located in close proximity to AP-1 elements. 
Mutation of either SAF-1 or AP-1 greatly affects the induction of the MMP-9 promoter and 
reduces the ability of SAF-1 and AP-1 to activate transcription (Ray et al., 2005). Among the 
cytokines capable of regulating MMP-9 expression, an important role is assigned to TNF-α. 
Alexander and Acott showed that TNF-α triggers the production of MMP-9 through the protein 
kinase C signal-transduction pathway (Alexander and Acott, 2001). Lau et al. showed TNF-α 
upregulated MMP-9 expression in coronary arteries (Lau et al., 2009) (Lau et al., 2008). Heat 
shock protein 60 has been shown to stimulate TNF-α followed by MMP-9 production in 
macrophages (Kol et al., 1998). In rat embryonic cardiomyoblast cell line H9c2, the NF-κB II 
binding site within the promoter region of MMP-9 (−626/−617) plays a key role in upregulation 
of MMP-9 expression by TNF-α induction (Wu et al., 2013). Among other cytokines capable of 
inducing MMP-9, IL-1β was shown to increase NF-κB and AP-1 in rat myocytes (Long, 2001). 
MMP-9 expression has been also reported in cardiomyocytes (He et al., 2011). Classical MMP-9 
activation includes disruption of the interaction between the zinc molecule in the catalytic domain 
and the cysteine switch in the pro-domain. This structural modification leads to the cleavage of the 
pro-form and production of active enzyme. MMP-9 is activated by other MMPs, including MMP-
2, -3, -13, -17, and -26   (Fridman et al., 1995)(Knäuper et al., 1997)(Ogata et al., 1992) (Uria and 
Lopez-Otin, 2000). For example, the activation of pro-MMP-3 by plasmin, which is generated 
from plasminogen by uPA bound to the uPA receptor on the plasma membrane, leads to activation 
of pro-MMP-9 (Ramos-DeSimone et al., 1999). Proteolytic enzymes, such as plasmin, urokinase-
type plasminogen activator, and tissue-type plasminogen activator, are capable of cleaving the pro-
domain to activate MMP-9 (Pepper, 2001). Another example of indirect pro-MMP-9 activation is 
through the initial activation of MMP-2 and -13 on the cell surface by membrane type-1-MMP 
(Fridman et al., 1995). Several serine proteases are capable of pro-MMP-9 activation. Tissue-
associated chymotrypsin-like proteinase activates pro-MMP-9 in skin tissues from chronic 
unhealed wounds (Han et al., 2002). Pancreatic trypsin-2 from human carcinoma was an effective 
pro-MMP-9 activator (Sorsa et al., 1997). Post-translational modifications of MMP-9 are another 
potent mechanism of increasing extracellular MMP-9 activity. These include S-nitrosylation 
and N-glycosylation. MMP-9 has one S-nitrosylation site at cysteine and two N-glycosylation sites 
at asparagines in positions 38 and 120 (Kotra et al., 2002) (Martínez-Ruiz and Lamas, 2004). 
Although MMP-9 is synthesized and secreted in a pro-form, there is evidence that MMP-9 may 
also be activated intracellularly. Pereira and colleagues reported that activated MMP-9 
accumulates in cells undergoing apoptosis, although this does not rule out the possibility that 
MMP-9 had been activated extracellularly and taken back up (Pereira et al., 2005). Tissue inhibitor 
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of metalloproteinase (TIMP)-1-free MMP-9 has been shown to accumulate in microvascular 
endothelial cells in endothelial vesicles after phorbol myristate acetate stimulation (Nguyen et al., 
1998). Future studies are warranted to determine whether MMP-9 can be activated intracellularly. 
Inhibition of MMP-9 is performed by TIMPs binding to the zymogen forms of the enzyme 
(Goldberg et al., 1992). All TIMPs are known to interact with MMP-9 and inhibit its activity (Brew 
and Nagase, 2010). TIMP-1 binds to pro-MMP-9, in addition to inhibiting its active form 
(Roderfeld et al., 2007). In circulation, α2 macroglobulin inhibits MMP-9 to prevent systemic 
MMP-9 activation. 
 
Figure 15. MMP-9 structure and factors regulation MMP-9 transcription and translation. (Yabluchanskiy et al., 2013) 
 
Finally, several ECM proteins are proteolytically processed by MMP-9, including elastin, 
collagen, fibronectin, and laminin. ECM fragments are known to express bioactive properties 
vascular remodeling (Trial et al., 2004). Laminin is a well-known MMP-9 substrate, and its levels 
negatively correlate with increased levels of MMP-9 (Horstmann et al., 2003). MMP-9 is known 
to process a number of inflammatory chemokines through proteolysis. MMP-9 processes CXCL5 
at the NH2 terminus and increases twofold its chemotactic activity (Van Den Steen et al., 2003). 
MMP-9 processes several cytokines, including TNF-α, IL-1β, and TGF-β. MMP-9 was shown to 
release active TNF-α from the cell surface via proteolysis, which results in the production of a 
biologically active mature form (Gearing et al., 1994). TGF-β is an anti-inflammatory cytokine 
and it is released in the extracellular space in a latent form. Its maturation is associated with 
several mechanisms, including proteolysis. MMP-9 can cleave the latent pro-form of TGF-β to 
its active state (Yu and Stamenkovic, 2000). 
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1.4 Molecular pathway included in abdominal aortic aneurysm 
Several molecular pathways are involved in the pathogenesis of AAA. Mediators of aortic 
damage include angiotensin II, leukotriene-LT4, prostaglandin- PGE2, interleukins, tumor 
necrosis factor, tissue plasminogen activator, c-Jun N-terminal Kinase, NF-kB, Rho kinases and 
osteoprotegerin. They activate matrix metalloproteinase, serine proteases and cysteine proteases. 
The result is the degradation of aortic wall proteins, extracellular matrix and the apoptosis of 
vascular smooth muscle cells. (Nanda et al., 2009) 
· Cytokines: Tumor Necrosis Factor-α (TNF-α) 
TNF-α is a 17 kDa nonglycosilated soluble protein, derived by the cleavage of the 32 kDa 
transmembrane precursor mediated by the TNF-α converting enzyme. TNF-α is a critical member 
of immune system and produces pro-inflammatory alteration in cells implicated in AAA. TNF-α 
activates a large spectrum of biological activities, among which the regulation of cell growth, 
differentiation, programmed cell-death and it also drives the inflammatory cascade events both 
under acute and chronic conditions TNF-α could have a central role in the aortic dilatation process 
by causing smooth muscle cell death and inducing the release of proteases that may weaken the 
aortic matrix. (Newman et al., 1994) Many investigations have demonstrated increased circulating 
and tissue levels of TNF-α in AAA patients particularly in small versus large aneurysm (Juvonen 
et al., 1997) (Hamano et al., 2003)(Satoh et al., 2004). These observations suggested a role for 
TNF-α in the early stage of aneurysm pathogenesis; this association was further confirmed by 
studies on animal models, showing that the inhibition of TNF-α protein could prevent aortic 
dilatation (Hingorani et al., 1998). Macrophages and lymphocytes are the main source of TNF-α, 
which exacerbates the inflammatory response mediating the release of adhesion molecules, such 
as VCAM-1 and ICAM-1, the lymphocyte proliferation and also stimulating the MMP secretion 
from both inflammatory and resident vascular cells, including SMC (Sarén et al., 1996)(Cohen et 
al., 2006).  
· c-Jun N-terminal Kinase 
c-Jun N-terminal Kinase (JNK) is highly activated in AAA (Yoshimura et al., 2005). JNK 
activity is crucial for secretion of MMP-9 and may participate in the proinflammatory cascade. 
(Bagowski and Ferrell, 2001) Consequently, inhibition of JNK resulted in the marked suppression 
of MMP activities, cellular infiltration and AAA development in mice. (Yoshimura et al., 2005)   
JNK activation has a pivotal role in ECM metabolism, its suppress genes encoding ECM proteins 
and biosynthetic enzymes, such as lox. Moreover, JNK activates numerous genes in the VSMC. 
Among JNK-induced genes, IL-1α, tropomyosin receptor kinase-C (TrkC), inducible nitric oxide 
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synthase, MMP-9 and lipocalin-2, are positive regulators of MMP-9 activity. NF-kB 
synergistically regulates the expression of MMP-9 with AP-1(Sato and Seiki, 1993), which is the 
major target of JNK pathway. NF-kB and the JNK pathway, however, may not always work 
synergistically, because NF-kB antagonizes the JNK pathway in TNF-alpha–induced apoptosis. 
(Papa et al., 2004)  
· Oxidative stress 
The existence of oxygen and nitrogen reactive species (ROS, RNS) in the aneurysm wall 
has been widely demonstrated. Oxidative stress includes a series of reactions which are mediated 
by the release of ROS and RNS by different cell types, inducing cell and tissue damage. These 
conditions depend on the increased ROS and RNS production, and/or the impaired activity of 
anti-oxidant systems, such as superoxide dismutases (McCormick et al., 2007). First evidences of 
ROS and RNS involvement in AAA pathogenesis derive from Dubick et al, that demonstrated a 
reduced activity of superoxide dismutase in aneurysm tissues, versus normal aorta (Dubick et al., 
1987). A comparative study between the aneurysm and the adjacent non-aneurysmal portion of 
patients undergoing surgical repair revealed a marked oxidative stress in the aneurysm segment 
evidenced by the increased expression of superoxide and NADPH oxidase, in comparison to the 
adjacent unaffected neighbours segments; moreover, the O2- increase was associated with 
inflammation, SMC depletion and elastin degradation (Miller et al., 2002). Cells from the 
inflammatory infiltrate constitute the main source of oxidative stress, especially macrophages 
generating large amounts of superoxide (O2-) and hydrogenperoxide (H2O2), thus further 
contributing to the inflammatory condition and the progression of the disease. Another source of 
reactive oxygen species is represented by vascular cells, including ECs, SMCs and adventitial 
fibroblasts. NADPH oxidase seems to play a key role in generating ROS and its activity may be 
influenced by several and different pathways, including cytokines released by inflammatory cells, 
lipid mediators, such as leukotrienes, oxidized LDL and growth factors. In addition, the 
mechanical stretch also exerts a decisive role, since it can stimulate SMC production of ROS 
through the activity of NADPH oxidase (McCormick et al., 2007). Oxidative stress can activate 
many biological responses promoting the aortic wall remodeling and dilatation, including 
osteopontin upregulation by ECs; activation of MMP and vSMC apoptosis.  
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     1.5 Future perspective: Epigenetic in AAA pathogenesis 
AAA is a complex disease caused by the interaction of environmental risk factors and 
genetics. Several mechanisms influence gene expression. The process of controlling gene 
expression through these method is known as epigenetics and includes RNA associated silencing, 
histone modifications and DNA methylation. (Jones, 2012) 
· Role of DNA methylation in AAA 
DNA methylation is a process in which a methyl group is added to a region where a 
cytosine nucleotide, located next to a guanine nucleotide, linked by a phosphate (CpG). A cluster 
of CpGs is called CpG island (CpGI). CpGIs are methylated by a group of enzymes called DNA 
methyltransferases. Insertion of methyl groups at CpGIs was thought to block the binding of 
transcription factors to promoters and therefore result in repressed gene expression.  
 
Figure 16. Overview of epigenetic processes. CpG methylation is characterised by the addition of a methyl group (CH3) to the 
5th carbon of a cytosine base that is 5′ to a guanine. DNA methyltransferase (DNMT) enzymes are responsible for this. CpG 
islands (dense regions of CpG dinucleotides within gene promoter regions) can have abnormally high (hyper) or low (hypo) 
levels of DNA methylation in many disease processes. DNA methylation of gene promoter regions inhibits gene transcription 
due to interference of the transcriptional binding complex essential for the recruitment of RNA polymerases. (Toghill et al., 
2015) 
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Changes to DNA methylation in genes controlling the regulatory cycles of ECM 
proteolysis can specifically influence phenotypic alteration of the structure and function of the 
ECM. Cigarette smoking (a risk factor for AAA development) is a powerful environmental 
modifier of DNA methylation and it is a potential mechanism by which tobacco can affect gene 
expression. Ryer et al. using isolated human mononuclear blood cells and controlling for smoking 
status, showed significant differences in DNA methylation at specific CpG island that mapped to 
two genes: CNN2 and SERPINB9 (Ryer et al., 2015). The first gene, CNN2, which is also known 
as h2-calponin or calponin, is an actin-binding protein implicated in cytoskeletal organization and 
vascular development. The second gene, SERPINB9 belongs to a family of serine protease 
inhibitors present in the cytoplasm of lymphocytes. SERPINB9 has been shown to inhibit 
apoptosis of human vSMCs, again a key process in AAA pathogenesis. In conclusion, DNA 
methylation has a potential role in the pathogenesis of AAA. (Toghill et al., 2015) 
 
·  Role of Micro-RNA in AAA 
Over the past decades, also micro-RNAs (miRs) have emerged as major post-
transcriptional regulators of gene expression and it has been shown to play key roles in vascular 
biology and cardiovascular diseases. (Wei et al., 2013)(Mcmanus and Freedman, 2015) (Caputo 
et al., 2015) Intracellular miRs mainly regulate gene expression through binding to their target 
messenger RNA, inhibiting their translation, or inducing their degradation. Briefly, miRNA is 
initially transcribed as primary miRNA (pri-miRNA), then processed into precursor miRNA (pre-
miRNA) by a microprocessor complex composed of Drosha and DiGeorge syndrome critical 
region 8 (DGCR8), pre-miRNA is then transported from the nucleus to the cytoplasm by exportin 
5, in presence of the Ran-GTP cofactor, and further processed into its mature form by Dicer. The 
miRNA is then recruited to the RNA-induced silencing complex (RISC) and it regulates the 
output of protein-coding genes through diverse mechanisms. The interaction of miRNAs with the 
3′ untranslated region (3′ UTR) of protein-coding genes is considered as the main mechanism, 
which usually leads to a decrease in protein output either by mRNA degradation or by 
translational repression. Recent studies have also suggested that miRNAs can interact with the 5′ 
UTR of protein-coding genes via complementarity and cause translational repression (Lytle et al., 
2007)  or activation of the targeted proteins (Ørom et al., 2008). The importance of miRs for 
vascular homeostasis becomes clear with the generation of mice with endothelial-specific 
depletion of Dicer that displayed postnatal angiogenesis defect. (Suárez et al., 2008) Many 
microRNAs have been identified to control crucial biological processes in cardiovascular system. 
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(Bonauer et al., 2010) For example, microRNA 143 and -145 were shown to control vSMC 
phenotype (Cordes et al., 2009) and microRNA-126 EC function. (Fish et al., 2008) Several 
clinical studies have been set up to identify microRNA as new biomarkers for AAA. Indeed, miRs 
were found up-regulated in aneurysmal tissue others down-regulated. Keiwa et al demonstrated 
that miRNA expression profile in human AAA wall tissue was quite different from the profile 
obtained from normal aortic wall tissue, including endothelial (let-7f and miR-20a, -21, -27, -92a, 
-126, -221, and -222) and inflammatory (miR-124a, -146a, -155, and -223) microRNAs. They 
found that vessel wall–related and inflammatory cell–derived miRNAs were significantly 
upregulated in aortic aneurysm wall tissue. These miRNA expression changes were closely 
correlated with inflammatory cytokines, including MCP-1, TNF-α, and TGF-β, which are 
responsible for AAA pathophysiology. Moreover, they analyzed the circulating miRNA 
expression profile of patients with AAA. Interestingly, miRNAs that were upregulated in human 
AAA wall tissue were significantly downregulated in plasma from patients with AAA. 
 
Figure 17. Main miRs identified in aortic tissues during AAA. mRs are differentially expressed during AAA, whether 
analysed in whole aortic tissue, or in distinct aortic layers such as the endothelium or the VSMC layer. mRs have also been 
identified in artery tertiary lymphoid organs that form in the adventitial layer during AAA. AAA, abdominal aortic aneurysm; 
ATLOs, artery tertiary lymphoid organs; VSMC, vascular smooth muscle cells; miRs, micro-RNAs. (Raffort et al., 2016) 
 
Recent studies showed that microRNA-29 plays a key role in AAA formation (Boon et 
al., 2011; Merk et al., 2012). These studies reported that inhibition of microRNA-29 reduces AAA 
in different murine models. In particular, microRNA-29 regulates the expression levels of 
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multiple targets with a function in ECM (collage, elastin and fibrillin), and the inhibition of 
microRNA-29 improves the structural integrity of vessel wall. Interestingly, inhibition of 
microRNA-29a, a member of microRNA-29 family, can also increase tropoelastin expression in 
venous vSMCs to increase elastin deposition in bioengineered vessels. (Rothuizen et al., 2016)  
In conclusion, clinical studies revealed concomitant deregulation of some miRs and their 
putative targets, some of them being key players in mechanisms involved in AAA formation, 
including inflammation, fibrosis, or ECM remodeling, suggesting potentially causal roles of miRs 
in the pathophysiology of human AAA. 
 
Figure 18. Implication of miRs in pathogenic pathways of AAA revealed by concomitant variation of miRs and their 
predicted targets. miRs are involved in ECM remodeling through their impact on the production of ECM components such as 
elastin or collagen or via a regulatory role on MMP activity. They regulate vascular cell homeostasis by targeting key molecules 
involved in cell proliferation, apoptosis, adhesion, and migration. They are also involved in the inflammatory process that 
characterizes AAA through their modulatory effects on immune cells and cytokine production. AAA, abdominal aortic 
aneurysm; Chi3l1, chitinase 3-like 1; COL1A1, collagen type 1, alpha 1; COL3A1, collagen type 3, alpha 1; COL5A1, collagen 
type 5, alpha 1; CTLA4, cytotoxic T-lymphocyte-associated protein; ECM, extracellular matrix; IL-3, interleukin-3; MCP-1, 
monocyte chemoattractant protein-1; MMP, metalloproteinase; PTEN, phosphatase and tensin homologue; RECK, reversion-
inducing cysteine-rich protein with kazal motifs; TGF-b, transforming growth factor beta; Th2, T-helper lymphocyte, type-2; 
TIMP3, tissue inhibitor of metalloproteinase-3; TNF-a, tumour necrosis factor alpha; VEGFA, vascular endothelial growth 
factor A; miRs, micro-RNAs; VSMC, vascular smooth muscle cell. (Raffort et al., 2016) 
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2. Aim of the project 
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The project is focused on the pathogenesis of aneurysms, in particular abdominal aortic 
aneurysm (AAA). This pathology is mainly related to the loosening of the biomechanical 
properties of the vessel wall. AAA is a multifactorial degenerative disease associated with 
inflammatory infiltrate, degradation of extracellular matrix (ECM) and apoptosis and phenotype 
switching of vascular smooth muscle cells (vSMC).  
The aim of this project was the study of the involvement of endothelial cells and 
endothelial MMP-9 in AAA progression. At this regard, the first part of the thesis is focused on 
histological analysis on AAA specimens. Moreover, in order to better understand the role of ECs 
and the role of endothelial MMP-9 in AAA progression, neo-angiogenesis and cell function in 
MMP-9-silenced ECs have been characterized. MMP-9 silencing was obtained through shRNA 
delivered by lentiviral vector. The role of matrix-metalloproteinase 9 (MMP-9) as a potential 
trigger of the inflammatory during the interaction between endothelial cells and vascular smooth 
muscle cells, and between endothelial cells and macrophages was characterized. This project 
investigates MMP-9 as a novel therapeutic target to restore vascular ECM in aneurysm context.  
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3. Material and Methods 
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3.1 Study of protocol and sample collection  
Aneurysm tissues of the abdominal aortic segment were provided by the Vascular Surgery 
Unit, University Hospital Maggiore, Novara. AAA tissues were collected from 15 patients (89% 
male, mean age 75±6) subjected to surgical repair; demographical and clinical data were reported on 
a database (Figure 21A). All samples were collected from donors correctly informed for the use of 
excessive pathological material for diagnostic and research purpose according to the local institute’s 
regulation and policies.  
Control aortic wall tissues derived from 3 healthy donors were provided from the 
Cardiovascular Tissue Bank, University Hospital S. Orsola-Malpighi, Bologna. Vascular tissues 
included in our study derive from the arterial segments not available for surgical use. Control aortic 
segments were selected according to two specific criteria: age between 18 and 55 years, to exclude 
ageing process; cause of death not associated with cardiovascular pre-existent affections, or brain 
haemorrhage.  
 
3.2 Immuno-histological analyses 
In order to characterize aortic wall and identify typical aneurysm features, AAA tissues were 
in part reserved for histological exam. Briefly, tissue samples were rinsed in phosphate-buffered 
saline (PBS) and fixed in 10% formalin for 48h at 4°C. Samples were subjected to several dehydration 
steps of 60 min incubation in solutions with increasing ethanol content (50%, 70%, 95% and 100%) 
and finally 1h incubation in xylene. Then, specimens were embedded in paraffin (Sherwood Medical, 
St. Louis, MO, USA) and serial sections were cut with a microtome (Leica- Jung, Germany) in 
consecutive 5 mm-thick sections. Rehydrated sections were stained with hematoxylin and eosin, 
weigert, sirius red, masson’s trichrome and alcian blue PAS stainings.  
Immunofluorescence and immunohistochemistry were performed on deparaffinized sections. 
For immunohistochemistry, after antigen retrieval (Sodium citrate buffer 10 mM, pH 6.0) with a 
pressure cooker, the primary antibodies were bound and detected using the VectaStain Elite Kit.  
Anti MMP-9 antibody was used (1:500, ThermoFischer, Italy). Reveal was performed by the 
use of diaminobenzidine (Vector Labs, US). Hematoxylin was used as counter staining (Sigma, Italy). 
Rabbit polyclonal anti-human C4d antibody has been used by an automated immunostainer (Ventana, 
Roche, Italy). All images were acquired using Pannoramic MIDI 3DHISTECH and analyzed with 
Pannoramic Viewer software (3DHISTECH, Hungary). 
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3.3 Gelatin zymography for detection of MMP-2 and MMP-9  
Human tissues from aneurysm and healthy tissues have been lysed with RIPA buffer (150mM 
sodium chloride, 1% Triton X100, 0,5% Sodium deoxycholate, 0,1% sodium dodecyl sulfate, 1mM 
EDTA, 1mM EGTA, 50 mM TRIS pH=8) supplemented with protease inhibitors (all from Sigma 
Aldrich, Italy). Protein samples and non-reducted conditioned media samples (FBS free conditions) 
obtained from endothelial cells were resolved by SDS-PAGE gels containing 0.2% gelatin (Sigma 
Aldrich). Briefly, after electrophoresis, gels were incubated with TRITON X-100 for 3h at room 
temperature, and then incubated overnight at 37°C in a solution of CaCl2 (1mM) and NaCl (15mM), 
pH 7.4 Following, gels were fixed and stained with coomassie blue. For objective quantification, 
ImageJ software has been used. 
 
 
Figure 19. Schematic representation of gelatin zymography  
 
 
 
3.4 Cell culture 
Human endothelial cells, EA.hy926 (ATCC® CRL-2922™) were cultured in high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) additioned with 10% fetal bovine serum and 
penicillin and streptomycin (100U/mL) and glutamine (2mM) (all from Euroclone, Italy) at 37°C in 
humid 5% CO2 atmosphere. Primary human aortic vSMCs (ATCC® PCS-100-012™) enriched with 
Vascular Cell Basal Medium (ATCC® PCS-100-030™) in the presence of Vascular Smooth Muscle 
Cell Growth Kit (ATCC® PCS-100-042™) and Penicillin-Streptomycin-Amphotericin B Solution 
(ATCC® PCS-999-002™). vSMCs were used up to the 8th passage. U-937 (ATCC® CRL-
1593.2™), human monocytes, were used for adhesion assays an endothelial monolayer. U-937 cells 
were cultured in RPMI-1640 medium additioned with 10% fetal bovine serum and penicillin and 
streptomycin (100U/mL) and glutamine (2mM). 
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3.5 Human peripheral blood mononuclear cells (PBMCs) isolation 
Human peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Paque™ 
Premium (GE Healthcare, Italy) density gradient centrifugation. Diluted peripheral blood (1:2 
dilution with PBS) was gently stratified on Ficoll-Histopaque solution and, then, centrifuged at 1500 
rpm for 30’. Blood components resulted separated according to their density: plasma, platelets and 
lymphocytes concentrate above the Ficoll, whereas erythrocytes and polymorphonucleated cells, in 
virtue of a higher density, concentrate below the Ficoll. The white cell ring was recovered and washes 
twice with PBS. To promote adhesion of isolated monocytes, peripheral blood mononuclear cells 
were cultured in serum-free RPMI medium. After 30 min, medium was replaced with RPMI 
containing 5% fetal bovine serum, and cells were cultured for 12 h. To generate macrophages, cells 
were cultured in DMEM with 10% fetal bovine serum, 1 mM sodium pyruvate, 1 mM non-essential 
amino acids, 0.25 mM HEPES (Lonza, Italy), and 10 ng/mL macrophage colony-stimulating factor 
(ImmunoTools, Germany) for 7 days. 
 
3.6 Cytofluorimetric analysis for macrophages characterization 
Cells, detached from culture dishes with 10 mM EDTA, were incubated for 30 min on ice with 
PE-labeled anti-CD11b and anti-105, FITC-labeled CD14, as suggested by the manufacturer's 
indications. Cells were analyzed by using a FACScalibur flow cytometer (BD Biosciences, Italy). 
 
3.7 Lentiviral vector transduction  
MMP-9 silencing was performed in EA.hy926 cells using lentiviral vector (LV) expressing 
shRNA targeting the human MMP-9. Two different shRNAs DNA sequences were acquired:  
shRNA1, TRCN0000373061 – CCGGGCCGGATACAAACTGGTATTCCTCGAG 
GAATACCAGTTTGTATCCGGCTTTTTG; and  
shRNA5, TRCN0000051438 –  
CCGGCCACAACATCACCTATTGGATCTCGAGATCCAATAGGTGATGTTGTGGTTTTTG. 
Third-generation LVs were generated as elsewhere described. (Follenzi and Naldini, 2002) 293T cells 
were cotransfected by calcium phosphate precipitation with the following four plasmids: 
pMDLg/RRE packaging plasmid; pMD2.VSV-G envelope-coding plasmid; pRSV-Rev and transfer 
vector plasmids for MMP-9 silencing as reported above. Thirty hours after transfection, culture 
supernatants containing the viral particles were collected and concentrated by ultracentrifugation. 
Collected viral particles were used to transduce 5*104 EA.hy926 with two different LVs (shRNA1 
and shRNA5). After 3 days of culture, cells were selected with puromycin (2.5 μg/mL) (Sigma, 
Aldrich, Italy) and used for the experiments. 
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3.8 Cytokines antibody arrays and immunofluorescent microscopy on EA.hy926 cells 
Supernatants collected from control and transduced EA.hy926 (shRNA 5+1) treated with 
human recombinant TNF-α (50ng/mL) for 24 hours were assayed for a wide panel of cytokines using 
a Human antibody Array (Panomics, Italy) following the manufacturer’s protocol. Briefly, 
supernatants collected from the different samples were incubated with the array membranes overnight 
at 4°C. After rinsing, the biotin-labeled detection antibodies have been added to the array membranes 
and incubated for 2 h. Then, streptavidin-HRP conjugated was added to the membranes and incubated 
for 1 hour. After rinsing, the array membranes were incubated with the detection solution and then 
cytokines panel was visualized using enhanced chemiluminescence ECL detection reagents in a 
chemisensitive visualizer (VersaDoc, BioRad, Italy). For immunofluorescence, anti-MCP-1 (1:50; 
ab9669, Abcam, UK) and anti-E-selectin (1:50; sc-14011, Santa Cruz Biotechnology, USA) primary 
antibodies were used following the procedures previously described in details. (Paragraph 3.2) 
 
3.9 Leukocyte-Endothelium Adhesion Assay 
U937 cell line -EA.hy926 adhesion assay was performed by Cell Biolabs’ CytoSelectTM 
Leukocyte-endothelium adhesion assay. Wild type and transduced endothelial cells were grown to 
80–90 % confluence in gelatin-coated 24-well plates, stimulated with 50 ng/ml TNF-a for 4 h. Then 
U937 were labelled by the LeukoTrackerTM solution for 1 h at 37 C and washed twice with growth 
medium. Labelled U937 were incubated together with endothelial cells. After 1 h of incubation, non-
adherent cells were removed by PBS rinsing. Adherent monocytes were counted in three separate 
fields per well by using an inverted fluorescence microscope. 
 
3.10 NF-kB activation  
1*104 ECs were cultured on cover slips in FBS free media overnight. After 10’, 30’ and 1 
hour of TNF-α stimulation, cells were fixed in 4% formalin, and labelled using p65 antibody (F-6, 
sc-8008, Santa Cruz, Biotechnology, USA). Then, immunofluorescence have been performed. In 
order to investigate phospho-p65-Ser 536, (sc-33020, Santa Cruz, Biotechnology, USA) and total p65 
expression the same timing was used for western blot assay. (Paragraph 3.12) 
 
3.11 Tube formation assay 
Growth factor–reduced Matrigel (Corning, USA) enriched with VEGF (200ng/mL), was 
plated in a 24 multi-well. After Matrigel jellification (37°C for 30 min), EA.hy926 wild type and 
transduced cells were seeded (1*105 cells per well) with 300µl of culture media. The cells were 
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incubated up to 6h at 37°C. Each well was observed and images were acquired using an inverted 
microscope equipped with digital camera. 
 
3.12 Western blot 
Cells were lysed in RIPA buffer. Protein concentration was determined using the 
bicinchoninic acid assay (Pierce, Rockford, IL, USA). 50 μg total proteins in sample buffer (62.5 mM 
Tris–HCl, pH 6.8, 20% glycerol, 5% β-mercaptoethanol, 0.5% bromophenol blue) were separated in 
SDS–PAGE electrophoresis and transferred to a nitrocellulose membrane (Amersham Biosciences, 
Buckinghamshire, UK). Blotted proteins were blocked with 5% non-fat dried milk in PBS, pH 7.4, 
for 1h at room temperature and incubated overnight with primary antibody. After rinsing three times 
with PBS 0.1% Tween 20, membranes were incubated with secondary antibody–peroxidase 
conjugates for 1h at room temperature. Protein bands were visualized using ECL detection reagents 
in a chemisensitive visualizer (VersaDoc, BioRad, Italy).   
 
3.13 Preparation of conditioned media (CM) and silver staining 
2.13*104/cm2 endothelial cells (wild-type and transduced cells) were grown to subconfluent 
density in 6-well culture plates in 10% serum-containing medium. After 16h, human recombinant 
TNF-α (50ng/mL; Sigma Aldrich, Italy) was added to serum-free medium, while wild-type or 
transduced EA.hy926 cells grown in the absence of TNF-α were used to determine MMP-9 basal 
expression. After 24h, media were collected as conditioned media (CM) and transferred to human 
vSMCs (5.4*103cells/cm2) for 24h. VSMCs cultured in the absence of CM were used as negative 
controls. Silver stain plus (161-0449 Bio-Rad, Italy) was performed on vSMC medium collected in 
the previously described conditions according to the manufacturer's instructions. A Congo Red-
elastin (5mg; E0502 Sigma-Aldrich, Italy) (15U of E1250, Sigma-Aldrich, Italy) was used as a 
positive control of proteolytic digestion. 
 
 
Figure 20. Flowchart of the experimental procedure. 
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3.14 Statistical analysis  
All the experiments were repeated at least three times. All data are expressed as mean values 
± standard deviation. The Student t test was performed to confirm the statistical significance of the 
obtained data. ** indicates p≤ 0,001 while * indicates p≤ 0,05. 
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4. Results 
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4.1 Study subjects: AAA patiens and control group. 
The analysis of the study involved two main groups, represented by I) aortic tissue derived 
from patients underwent surgical repair for abdominal aortic aneurysm provided by the Vascular 
Surgery Unit of Ospedale Maggiore in Novara; and II) aortic tissues derived from healthy donor 
collected from the Cardiovascular Tissue Bank of S. Orsola-Malpighi Hospital (Bologna). Clinic 
features of AAA patients, such as demographical data, cardiovascular risk and pharmacological 
treatments (B-blockers, statin, antiplatelet drugs, oral anticoagulant and ACE inhibitors) were 
recorded prospectively in a database. Figure 21A summarized patient clinical data.  
Regarding the control group, we selected aortic tissues deriving from healthy donors of arterial 
segment, not available for surgical purpose by Cardiovascular Tissue Bank. Selection criteria 
excluded vascular segments affected by calcifications and included cause of death not associated with 
cardiovascular affections.  
 
 
Figure 21. A) Clinical features of AAA patients. DAAA diameter aneurysm, COPD Chronic obstructive pulmonary disease, 
CRF chronic renal failure. B) 3D image of aneurysm C) Computed Tomography (CT) is the gold standard for the diagnosis 
of AAA. 
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4.2 Histological features of aneurysm-affected abdominal aorta 
Histological stainings were performed on 5 µm sections of AAA and control groups. In 
presence of aneurysms, the vessel wall microstructure resulted significantly modified. Distinctive 
feature of AAA is represented by the complete loss of the vessel wall architecture, so the three wall 
layers could not be distinguished; this condition is due to the loss of muscular tone and extensive 
medial degeneration, as observed by histological analyses. In addition, aneurysmal aortae had 
significantly increased adventitial vasa vasorum densities and in the medial layer compared with 
controls. AAA is associated with the high degree inflammatory infiltrate: this aspect can be revealed 
by the presence of many immune cells, including lymphocytes and macrophages as shown in 
haematoxylin-eosin staining. (Figure 22A) Moreover, AAA is characterized by a loss of vSMCs. In 
control tissues, the majority of cells in the tunica media are smooth muscle cells represented by 
elongated nuclei, and in the medial layer cells are strongly positive to alpha-sma antibody. (Figure 
22B) Smooth muscle cells and collagen fibres are found between the layers of elastic fibres in the 
media layer. The subendothelial layer of connective tissue is characterised by a lower density of cells, 
i.e. fewer nuclei. 
 
Figure 22. Representative stainings on control and AAA sections. A) Hematoxylin/eosin on CTRL, scale bar 200µm; and 
hematoxylin/eosin on AAA, 2000µm; adventitia and media layers 100µm. B) Representative immunhistochemistry anti-alpha-sma 
staining on healthy tissue, scale bar 200µm, and on medial layer of AAA, scale bar 200µm. 
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In AAA, Masson’s trichrome and Sirius Red showed thickening of collagen fibers. (Figure 
23C and 23F) Elastic fibers in the medial layer were irregularly arranged and frequently fragmented, 
instead, in control aortae, elastic fibers had regular black linear structures, as shown by Weigert 
staining. (Figure 23I). In aneurysms, alcian-blue PAS staining showed cystic medial necrosis (CMN). 
(arrows in Figure 23L) CMN is a disorder of large arteries, such as aorta, characterized by an 
accumulation of basophilic ground substance in the media with cyst-like lesions. 
 
 
Figure 23. Representative histological stainings performed on control and AAA sections. Masson thricrome and sirius red show 
collagen contenent, Weigert is performed for elastic fibers and AB-pas for cystic medial necrosis. Scale bar 200µm 
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The thickening of aortic wall observed in presence of AAA decreases the amount of nutrients 
and oxigen that cells receive by diffusion, which is further accentuated by the presence of intra-
luminal thrombus, leading to relative hypoxia. Neoangiogenesis occurs as a part of an adaptive 
response to survive in a relatively hypoxic environmental. 
Indeed, medial neo-angiogenesis was found in the medial layer of aneurysm samples as shown 
by hematoxylin and eosin staining. (Figure 24)  Interestingly, a strong positive C4d immunostaining, 
indicating that an inflammatory signal specific for the formed medial endothelial structure was 
present. (Figure 24)  A unique feature of C4d is that it binds covalently to the endothelial and collagen 
basement membranes. Thus, the accumulation of C4d indicates a chronic inflammatory events 
sustained by ECs. 
 
 
Figure 24. Representative hematoxylin-eosin performed on control  and AAA: medial neo-angiogenesis is shown. (Arrows) 
Scale bar: 200 µm. Representative immunohistological staining for C4d. Scale bar: 200 µm 
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MCP-1, a monocyte chemotactic factor that signals via the CCR2 receptor, is critical for 
aneurysm formation because of its ability to recruit leukocytes that, in turn, produce ECM-degrading 
MMPs, thereby inducing aortic wall remodeling and dilatation.  
Among vascular cytokines, IL-6 is well known to be secreted at high levels in human aortic 
aneurysm disease. It has been identified as an independent biomarker of severe coronary artery 
disease and it is associated with an increased risk for aneurysm rupture. In fact, aneurysms showed a 
significant upregulation of both, MCP-1 and IL-6 as shown by immunofluorescence stainings. (Figure 
25) MCP-1 (red) was identified in both the endothelium and the medial layer. IL-6 (green) was 
predominantly detected in the adventitia, in proximity of vasa vasorum, and it was barely detectable 
in the media and intima. Abdominal aorta controls were negative for all these markers. 
 
 
Figure 25.  Representative immunofluorescence analysis for MCP-1 and IL-6 on control and AAA tissues. Scale bar: 200 µm 
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4.3 MMP-9 expression within healthy and AAA wall 
MMP-9 involvement in pathological aortic remodeling contextually to AAA, was 
demonstrated by zymography assay. Zimography assay showed a significant increase in MMP-9 
expression in aneurysmatic tissues compared to control. (Figure 26A) Aortic wall affected by 
aneurysm contains several cell types as possible source of MMP-9. As expected, high expression of 
MMP-9 in serial sections of AAA specimens, but not in normal tissue, were observed. (Figure 26B) 
In these sections, MMP-9 was detected in the inflammatory infiltrate. The high concentration of 
inflammatory cells observed in these specimens was probably due to the transmural migration of 
circulating cells in response to chemotactic factors; moreover, vascular resident cells greatly 
contribute to the secretion of MMPs, in particular MMP-9. In good agreement with this, in medial 
neo-angiogenesis, where ECs are present, MMP-9 expression was observed. (Figure 26B) As 
previously shown, the aneurysmatic vessel wall microstructure resulted significanlty altered, and neo-
aniogenesis was evident in the medial layer.  
 
Figure 26. A) Representative gelatin zymography assay and relative densitometry on fresh tissues (control and AAAs from 
different patients) n value=3. B) Representative immunohistochemistry for MMP-9 on control tissue. Scale bar: 200 µm and 
100 µm  and representative immunohistochemistry on AAAs. Scale bar: 1000 µm and 100 µm. 
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4.4 In vitro model of ECs silenced for MMP-9  
Since ECs play a key role in wall dysfunction, and previous data on human samples confirmed 
the role of MMP-9 in aneurysm development, we sought to determine whether lack of endothelial 
MMP-9 could affect EC-mediated matrix remodeling. For this purpose, we silenced MMP-9 gene 
expression in EA.hy926 cells using lentiviral-transduced shRNA. First, EA.hy926 cells were co-
transduced with a combination of various LVs: shRNA1+shRNA1; shRNA1+shRNA5; 
shRNA5+shRNA5, and shRNA5+shRNA1. Subsequently, MMP-9 protein expression was measured 
in transduced cells treated in presence of TNF-α (50ng/mL).  To compare the expression of MMP-9 
in cell lysates and in supernatants, immunoblotting and zymography assay (Figure 27A and Figure 
27B respectively) were performed. As expected, a significant downregulation of both proMMP-9 and 
MMP-9 in lysates of shRNA5- and/or shRNA1-transduced EA.hy926 cells compared to control cells 
(Ctrl) was observed (Figure 27A). Likewise, secreted MMP-9 was significantly down-regulated 
following MMP-9 gene silencing, albeit to different extents (Figure 27B). Moreover, after TNF-α 
treatment wild-type EA.hy926 showed a significant upregulation of MMP-9, which was strongly 
inhibited in shRNA5+shRNA1-transduced cells (Figure 27C). 
 
Figure 27. MMP-9 silenced EA.hy926 cells. A) Western blot and relative densitometry of control and shRNA lentiviral-transduced 
EA.hy926 cells using antibodies against MMP-9 and tubulin. Relative densitometry value s obtained from three different experiments 
are expressed as mean±SD. n value=3. * indicates p≤0,05; ** ≤0,001. 
B) Zymography assay performed on control and transduced EA.hy926 endothelial cells stimulated with human recombinant TNF-α 
(50ng/mL). Peripheral blood was used as standard. n value =3. C) Representative immunofluorescence staining for MMP-9 on wild 
type and transduced cell. Basal control (without TNF-α) did not express MMP-9. n value=3. Scale bar: 40 µm 
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4.5 Tube formation assay 
We assessed the ability of ECs void of MMP-9 to promote tube formation in vitro. When wild-
type EA.hy926 cells were placed on growth factor-reduced Matrigel upon VEGF stimulation, 
elongated, cross-linked, and robust cord-like structures were observed. Remarkably, VEGF-induced 
tube formation was strongly impaired in EA.hy926 lacking MMP-9. (Figure 28) Thus, data indicate 
that MMP-9 is required for EA.hy926 cell migration and angiogenesis. 
 
Figure 28. Tube formation assay in Matrigel matrix. 
 
4.6 NF-kB activation 
Since TNF-α induces the inflammatory response through NF-kB activation in ECs, we sought 
to determine whether MMP-9 silencing could affect TNF-α-mediated induction of NF-kB. As 
expected, an early and transient upregulation of phospho-p65 protein in wild-type EA.hy926 cells 
treated with TNF-α was observed, whereas p65 remained unaltered. In contrast, in EA.hy926 
shRNA5+shRNA1-transduced cells, TNF-α-mediated phosphorylation of p65 was completely 
inhibited. (Figure 29) 
 
Figure 29. NF-kB activation. Western blot and relative densitometry for phospho p65 and p65 expression. * indicates p≤0,05; 
** ≤0,001. 
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Western blot was further confirmed by immunofluorescence assay where a marked nuclear 
translocation was shown after 10 minutes in wild type cells treated with TNF-α. (Figure 30) After 30 
minutes, a decrease of nuclear positive staining was observed, while no nuclear p-65 signal was 
present after 60 minutes. On the other hand, in MMP-9 silenced cells no p-65 nuclear translocation 
was observed. (Figure 30) 
 
Figure 30. Representative immunofluorescence staining for p-65. n value=3. Scale bar: 40 µm 
 
4.7 MMP-9 regulates cytokines production by ECs and inflammatory cells adhesion 
In order to determine whether endothelial-produced MMP-9 may promote a pro-inflammatory 
autocrine loop through regulation of cytokine expression, cytokine antibody arrays on conditioned 
media from WT- or shRNA5+shRNA1-transduced cells were performed. Briefly, following 24h 
incubation in free-FBS medium in the presence or absence of TNF-α (50ng/mL) the conditioned 
media were collected. In the conditioned media derived from MMP-9-silenced EA.hy926 cells, 
reduced expression of several cytokines and growth factors was observed: GM-CSF (16%), IL-3 
(8%), IL-5 (32%), IL-6 (34%), IL-7 (38%), IL-8 (9%), MCP-2 (41%) and MCP-3 (30%), where each 
percentage in bracket represents cytokine expression relative to non-transduced EA.hy926 control 
cells. (Figure 31A) 
To validate cytokine array data, immunofluorescence assay on cells similarly treated was 
performed. In wt-EA.hy926-treated cells, an upregulation of MCP-1 expression was observed, 
whereas in transduced cells was significantly reduced. (Figure 31B) Likewise, TNF-α-mediated 
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activation of E-selectin (CD62E) was inhibited in MMP-9-silenced EA.hy926 cells, but not wild type 
cells.  
 
 
Figure 31. MMP-9 affects the inflammatory response in ECs. A) Cytokines assay performed on conditioned medium (CM) 
obtained from wild type and transduced (shRNA 5+1) endothelial cells treated with TNF-α in starving conditions. n value=3 B) 
Representative immunofluorescence for E-selectin (CD62E) and MCP-1 on wild type and transduced EA.hy926. . n value=3 
 
Since CD62E plays an important role in leukocytes recruiting, the effects of lack of MMP-9 
on U937 cell adhesion was determined. Indeed, MMP-9 silenced cells showed a 3-fold decrease in 
U937 adhesion in response to TNF-α treatment compared to wild-type cells similarly stimulated. 
Thus, lack of endothelial MMP-9 affects EC-mediated secretion of pro-inflammatory cytokines. 
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Figure 32. U937 adhesion on ECs. * indicates ** ≤0,001. n value = 3 
 
4.8 Effect of conditioned media (CM) on vascular smooth muscle cells (vSMC) and 
macrophages  
In order to characterize the role of MMP-9 in the interaction between ECs, vSMCs and 
macrophages, the effect of conditioned medium (CM) obtained from wt- or shRNA 5+1-transduced 
EA.hy926 cells on vSMC pro-angiogenic functions and on macrophages was assessed.  
First, MMP-9 expression in vSMCs cultured in either wt- or transduced endothelial cell-
derived CM was measured. As negative control, lysates from vSMCs grown in non-conditioned 
medium (basal) were similarly isolated. (Figure 33) As expected, MMP-9 in vSMCs cultured in basal 
medium could not be detected. (Figure 33)  
Interestingly, vSMCs grown in EA.hy926 cell-derived CM showed enhanced MMP-9 
expression as compared to cells grown with basal medium, suggesting that EA.hy926 cells secrete 
pro-angiogenic factors able to induce MMP-9 expression. (Figure 33) Intriguingly, also lysates from 
vSMCs cultured with shRNA5+1-transduced EA.hy926 cells showed higher MMP-9 expression than 
basal, implying that this effect is independent from MMP-9 expression in EA.hy926 cells. When 
MMP-9 expression was measured in vSMCs grown in CM obtained from wt-EA.hy926 cells treated 
for 24h with TNF-α, further upregulation of MMP-9 expression was observed. (Figure 33) In contrast, 
when CM obtained from MMP-9-silenced EA.hy926 cells is used, TNF-α-mediated activation of 
MMP-9 was almost inhibited (Figure 32), suggesting that MMP-9 expression in EA.hy926 cells 
mediates, in part, vSMC-mediated angiogenesis. To further address this hypothesis, the extent of 
proteolytic cleavage of elastin in the different conditioned and basal media was compared. 
Remarkably, TNF-α treatment induced proteolytic cleavage of elastin in medium from vSMCs 
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cultured with wild-type EA.hy926 cell-derived CM, but not shRNA 5+1 transduced cell-derived CM, 
suggesting that endothelial MMP-9 silencing ultimately inhibits elastin fragmentation also in pro-
inflammatory conditions. (Figure 33)  
IL-6, it is highly modulated by the presence of TNF-α. However, wild-type endothelial CM 
did not show any significant effect with respect to basal medium, indicating that no pro-inflammatory 
stimuli were present. In fact, when in presence of TNF-α, IL-6 resulted significantly up-regulated. 
(Figure 33B) Moreover, data suggest that CM of wild type EC, enriched with TNF-α, contains more 
pro-inflammatory mediators with respect to CM of MMP-9 silenced cells enriched with TNF-α. In 
fact, in this case, IL-6 resulted significantly decreased with respect to CM obtained from wild-type 
ECs. Moreover, together with MMP-9 up-regulation, vSMCs cultured with wild type CM enriched 
with TNF-α showed a proteolytic elastin capability. In fact, only in the lane corresponding to vSMCs 
cultured with CM containing TNF-α obtained from wild type ECs showed a smear, comparable with 
the lane corresponding to elastin digested with elastase. (Arrow in Figure 33C) 
 
Figure 33. A) Western blot on MMP-9 and relative densitometry performed on vSMCs cultured with CM obtained from wild 
type and transduced EA.hy926 endothelial cells treated TNF-α (50ng/mL)  Significance has been evaluated with respect to 
basal culture conditions with p≤0,001.  B) Western blot on IL-6 and relative densitometry performed on vSMCs cultured 
with CM obtained from wild type and transduced EA.hy926 endothelial cells treated TNF-α (50ng/mL)  Significance has been 
evaluated with respect to basal culture conditions with p≤0,001. C) Silver staining on cell culture media. Elastin digested with 
elastase has been used as standard. 
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Finally, macrophages have been cultured for 24h with Conditioned Medium (CM) obtained 
from wild-type and transduced (shRNA 5+1) endothelial cells. Macrophage phenotype has been 
characterized by specific surface markers such as CD14, CD11b and CD105. (Figure 34B) 
Macrophages maintained with CM obtained from ECs for 24 hours, showed no differences related to 
MMP-9 and IL-6 expression with respect to basal, also in presence of CM obtained from transduced 
cells. (Figure 34C and 34D) These data showed that endothelial MMP-9-silenced has a specific effect 
on vSMCs, without affecting macrophages behavior.  
 
 
 
 
Figure 34. A) Macrophages morphology after 7 days of differentiation media. B) FACS analysis for macrophages markers C) 
Western blot on MMP-9 and relative densitometry performed on macrophages cultured with CM obtained from wild type 
and trasducted EA.hy926 endothelial cells treated TNF-α (50ng/mL)  Significance has been evaluated with respect to basal 
culture conditions with p≤0,001.  B) Western blot on IL-6 and relative densitometry performed on macrophages cultured 
with CM obtained from wild type and trasducted EA.hy926 endothelial cells treated TNF-α (50ng/mL)  Significance has been 
evaluated with respect to basal culture conditions with p≤0,05. 
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5. Discussion 
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Vascular diseases display a heterogeneous localization along the aorta. Aortic aneurysms can 
develop in both the thoracic (TAA) and abdominal aorta (AAA). However, TAA and AAA have 
pathogenesis. AAA has a higher incidence with respect to TAA. Moreover, the majority of these 
aneurysms have an atherosclerotic nature. (Ladich et al., 2016) In fact, abdominal aortic media has 
peculiar morphological characteristics, consisting in a decreased elastin content corresponding to a 
reduced number of lamellar units (28-32), in comparison to the thoracic segment (55-60). This aspect 
makes abdominal aorta more susceptible to aneurysm event. (Ruddy et al, 2008) 
AAA is partially characterized by dramatic modifications of the endothelial, medial and 
adventitia layers (Daugherty et al., 2000). These modifications are: presence of intraluminal 
thrombus, calcification, inflammatory cell infiltrate, loss of medial vSMC phenotype, elastin 
degradation and collagen replacement resulting in a thin fibrotic wall.  (F. A. M. V. I. Hellenthal et 
al., 2009) In particular, in the medial layer, AAA is histologically typified by vSMC depletion and 
degradation of ECM (loss of alpha-smooth muscle actin-positive cells in aneurysm tissues respect to 
healthy aortas). Elastin content is limited, structure results fragmented and altered, while there is high 
collagen content.  
In human aorta, ECM turnover is a physiologic process, necessary for the maintenance of 
tissue homeostasis. This physiological remodeling is mediated by proteolytic enzymes, among which 
MMPs are the most characterized and studied. However, MMPs are also responsible for ECM 
degradation during tissue remodeling when in presence of pathological conditions. Several MMPs 
have been studied in relation to AAA, such as MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and their 
inhibitor called TIMPs. MMP-9 robustly increases during several cardiovascular diseases, including 
hypertensions, atherosclerosis and myocardial infarction. (Yabluchanskiy et al., 2013) In particular, 
in AAA, MMP-9 stimulates the immune response to initiate pathogenesis and exacerbate the disease 
progression through proteolytic degradation of proteins in the basal lamina of blood vessels as well 
as the release of the biologically active form of VEGF. (Bergers et al., 2000) Furthermore, MMP-9 
serum levels significantly correlate with aneurysmal tissues. (Stather et al., 2014)  
AAA is histologically characterized by an accumulation of inflammatory cells, (Wang et al., 
2014) and the inflammatory process contributes to a loss of contractile SMC phenotype. (Beamish et 
al., 2010) In particular, the presence of inflammatory cells is correlated to high level of IL-6 and 
MCP-1. Moehle et al. showed that MCP-1 is required for AAA formation in terms of macrophages 
recruitment and vSMC phenotype modulation in mice. (Moehle et al., 2011) Wang et al. demonstrated 
recombinant MCP-1 induced IL-6 expression in human macrophages, and IL-6 exposure time-
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dependently induces vSMC apoptosis via Stat1. In this context they found a MCP-1/IL-6 regulatory 
loop between vSMC and macrophages.(Wang et al., 2015) 
     Medial neo-angiogenesis, which leads to hyper-permeable vessels together with ECM 
degradation, indicates that endothelial cells play a key role in wall dysfunctions. (Jones, 2011) 
However, the specific role of ECs still remains poorly understood. The observation that medial neo-
angiogenesis leads to increased vascular permeability and ECM degradation indicates that ECs play 
a key role in wall dysfunction. Furthermore, during neo-angiogenesis within the medial layer, human 
AAA expresses high levels of C4d, a degradation product of the classic complement pathway, which 
covalently binds to the endothelial and collagen basement membranes. (Josephson, 2014) Thus, the 
accumulation of C4d is a hallmark of EC chronic inflammation.   
   In order to better understanding the role of ECs and the role of endothelial MMP-9 in AAA 
progression, EA.hy926 cells silenced for MMP-9 have been used. MMP-9 silencing was performed 
through short hairpin-RNA (shRNA) delivered by lentiviral vector (LVs) which represent a valuable 
tool for gene therapy in that they are able to transduce non-dividing cells, integrate into the genome 
of target cell with high levels and long-term transgene expression and accommodate relatively large 
genes. RNA interference (iRNA) is a potent and specific mechanism for regulating gene expression 
whose inhibitory effect results from selective degradation of target mRNA. (McManus and Sharp, 
2002) Data clearly showed that tube formation activity of MMP-9-silenced EA.hy926 cells is 
impaired, implying that MMP-9 is required for matrix remodeling.  
Previous data showed that the recruitment of inflammatory cells is sustained by a chemotactic 
gradient due to cytokines released through EC activity, and by the increased expression of adhesion 
molecules able to interact with circulating inflammatory cells. These cytokines include TNF-α, ILs, 
lymphokines, monokines, interferons, colony stimulating factors, and transforming growth factors, 
although these cytokines are produced by cell types other than ECs, such as macrophages, T cells and 
monocytes, as well as platelets and VSMCs. (Sprague and Khalil, 2009) Among these inflammation 
mediators, TNF-α plays a pivotal role in the initiation and progression of vascular disorder by 
modulating the expression of molecules involved in vascular tone, inflammation and remodeling, 
thus, inducing endothelial dysfunction. (Zhang et al., 2009) (Palmieri et al., 2014) In particular, TNF-
α-mediated activation of NF-kB has been shown to be one of the major pathway contributing to 
inflammation-mediated tissue damage. Thus, the goal of this work has been investigating whether 
lack of endothelial MMP-9 could impair TNF-α/NF-kB signalling pathway. Data clearly showed that 
both TNF-α-mediated phosphorylation of p65 and p65 nuclear translocation, characteristics of NF-
kB activation, were significantly decreased in EA.hy926 cells silenced for MMP-9. Thus, MMP-9 
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plays a role during TNF-α-mediated activation of NF-kB. Remarkably, MMP-9 silencing showed an 
autocrine effect on ECs since several cytokines resulted down-regulated, especially IL-6, IL-7, MCP-
1. As it is well-established that TNF-α-mediated upregulation of these cytokines requires unaltered 
NF-kB signaling, these findings indicate that also MMP-9 regulate cytokine production in ECs during 
matrix remodeling. Data show also that lack of endothelial MMP-9 affects TNF-α-mediated 
upregulation of CD62E, a selectin that mediates leukocyte cell adhesion to activated platelets and 
other leukocytes in response to TNF-α, IL-1β or LPS, thereby initiating multicellular adhesive and 
signaling events during physiological or pathological inflammation processes. (McEver, 2015) Thus, 
data indicating the requirement of MMP-9 for TNF-α-mediated upregulation of CD62E consistent 
with the observation that MMP-9 released from ECs represents a fundamental switch able to control 
the inflammatory response. In this regard, MMP-9 has been shown to release active TNF-α from the 
cell surface via proteolysis. (Gearing et al., 1994) 
Results also support the knowledge that TNF-α mediates the inflammatory response in ECs. 
TNF-α is an activator of NF-kB which plays a central role in the development of the inflammatory 
response through further regulation of genes encoding not only pro-inflammatory cytokines, but also 
adhesion molecules, such as CD62E, VCAM-1 and ICAM-1, chemokines, growth factors, and 
inducible enzymes such as cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS). 
NF-κB is also required for cytokine upregulation of MMP-1, -3 and -9. (Bond et al., 2001)  
Since the vascular inflammatory response involves complex interaction among white cells 
(i.e. neutrophil, lymphocytes, monocytes and macrophages) ECs and vSMC, the influence of MMP-
9 secreted by ECs on vSMCs competence in vessel wall matrix remodeling and weakening was 
assessed. In literature, two different co-culture methods outlined from several studies on 
atherosclerosis. Indirect co-cultures are useful to investigate cell responses between different cell 
types that involve secretory pathways and cytokine production. They are widely used to study 
different diseases through in vitro models. The main variations of the indirect co-culture models are 
microcarrier, scaffold, bilayer, conditioned media (CM) and trans-well methods. In this work, indirect 
co-cultures were performed. In particular, previous reports have shown that co-culturing of human 
aortic ECs and vSMC along with monocytes led to increased enrichment in cell culture medium of 
matrix remodeling effectors such as fibronectin, collagen, IL-1 and IL-6. (Ghosh et al., 2015) 
Data show that CM obtained from ECs cultured in the presence of TNF-α upregulate MMP-9 
expression level in vSMCs, suggesting that this CM contains a sufficient amount of inflammatory 
molecules able to stimulate vSMCs functions. Interestingly, treatment of vSMCs with CM derived 
from MMP-9-silenced EA.hy926, exposed to TNF-α, led to a dramatic inhibition of MMP-9 
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expression levels. This finding might be explained, in part, by the assumption that CM derived from 
MMP-9-silenced EA.hy926 cells contains lower levels of cytokines, growth factors, and adhesion 
molecules required for EC-mediated activation of vSMC functions during neo-angiogenesis. In 
support to this conclusion, CM from MMP-9-silenced EA.hy926 cell, but not wild type cells, did not 
display proteolytic activity in terms of elastin degradation in vitro. 
In blood vessels, elastin is synthetized and secreted by vSMCs. (Patel et al., 2006) In the event 
of injury, the production of tropoelastin can be quickly restored and it is influenced by several 
exogenous factors such as TNF-α, IL-1β, insulin-like growth factor-1 and strongly by transforming 
growth factor. (Pierce et al., 2006) MMPs are particularly important in elastin breakdown, and MMP-
2, -3, -9 and -12 can directly degrade elastin. (Ra and Parks, 2007) Moreover, elastin fragments 
promote monocyte/macrophage recruitment in vivo.(Adair-Kirk and Senior, 2008) Thus, consistently 
these findings, data suggest that ECs have a humoral cross-talk with vSMCs, that can locally sustain 
the pathogenesis of AAA, and open new scenarios concerning the role of EC-produced MMP-9 in 
AAA development.  
Although, these data demonstrate that medial layer ECs play a key role in the pathogenesis 
and maintenance of AAA in situ through regulation of vSMC functions, which ultimately promotes 
ECM damage. Importantly, the fact that MMP-9-silenced ECs are no longer able to migrate and 
differentiate in a three dimensional matrix strongly indicates that MMP-9 regulates proangiogenic 
EC functions as well.  
In conclusion, the experimental approach used in this study opens new perspective for the 
treatment of AAA. In this regard, the advancement of more than 20 therapeutic siRNAs into the clinic 
indicates that RNAi-based medicine holds promise as future therapeutic option for AAA. However, 
several obstacles in clinical development of RNAi-based therapeutics, foremost the delivery methods 
to target cells, are yet to be overcome. (Burnett et al., 2011)  
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